[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 10861
1. Leach P, Abou-Zeid AH, Kearney T, Davis J, Trainer PJ, Gnanalingham KK: Endoscopic transsphenoidal pituitary surgery: evidence of an operative learning curve. Neurosurgery; 2010 Nov;67(5):1205-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: There were 67 patients (54%) with nonfunctioning adenomas, 22 (18%) with acromegaly, and 10 (8%) with Cushing's disease.
  • Between study periods 1 and 2, there was a decrease in the mean duration of surgery for nonfunctioning adenomas (from 120 minutes to 91 minutes; P < .01).
  • This learning effect was not apparent for functioning adenomas, the surgery for which also took longer to perform.
  • There were nonsignificant trends toward improved endocrine remission rates for patients with Cushing's disease (from 50% to 83%), but operative complications, notably the rates of hypopituitarism, did not change.

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20871457.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


2. Mantovani G, Lania AG, Spada A: GNAS imprinting and pituitary tumors. Mol Cell Endocrinol; 2010 Sep 15;326(1-2):15-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Accordingly, mutations of the alpha subunit of the stimulatory G protein gene (GNAS) leading to the constitutive activation of adenylyl cyclase (the so-called gsp oncogene) have been found in a significant proportion of GH-secreting pituitary adenomas.
  • Due to the monoallelic origin of Gsalpha in normal pituitary gsp mutations occur on a maternal allele in order to have a phenotypic effect in both sporadic GH-secreting adenomas and those associated with the McCune-Albright syndrome.
  • Therefore, genetic and epigenetic alterations of the GNAS gene, with subsequent dysregulation of the cAMP pathway, appear, to date, the only molecular hallmark of most GH-secreting adenomas.
  • [MeSH-minor] Animals. Cyclic AMP-Dependent Protein Kinases / metabolism. Fibrous Dysplasia, Polyostotic / genetics. Genomic Imprinting. Growth Hormone-Secreting Pituitary Adenoma / genetics. Humans. Mice. Pituitary Gland / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20398730.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases; EC 3.6.1.- / GNAS protein, human; EC 3.6.1.- / Gnas protein, mouse; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gs
  •  go-up   go-down


3. Mendoza PL, Ongkeko EE, Santiago JF: Silent parathyroid adenoma mistakenly interpreted on FDG-PET as thyroid cancer metastasis in a patient with elevated thyroglobulin and negative I-131 whole body scan and removed by radioguided minimally invasive surgery. Clin Nucl Med; 2008 Jan;33(1):23-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Silent parathyroid adenoma mistakenly interpreted on FDG-PET as thyroid cancer metastasis in a patient with elevated thyroglobulin and negative I-131 whole body scan and removed by radioguided minimally invasive surgery.
  • Histopathology, however, revealed a parathyroid adenoma.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097251.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 9010-34-8 / Thyroglobulin; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


Advertisement
4. Gopan T, Remer E, Hamrahian AH: Evaluating and managing adrenal incidentalomas. Cleve Clin J Med; 2006 Jun;73(6):561-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The attenuation coefficient on noncontrast computed tomography (CT), expressed in Hounsfield units (HU), is better than tumor size in differentiating adrenal adenomas and hyperplastic lesions from nonadenomas.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis
  • [MeSH-minor] Aldosterone / blood. Biomarkers, Tumor / blood. Biopsy, Fine-Needle. Diagnosis, Differential. Humans. Hydrocortisone / blood. Magnetic Resonance Imaging. Prevalence. Renin / blood. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16784156.001).
  • [ISSN] 0891-1150
  • [Journal-full-title] Cleveland Clinic journal of medicine
  • [ISO-abbreviation] Cleve Clin J Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 4964P6T9RB / Aldosterone; EC 3.4.23.15 / Renin; WI4X0X7BPJ / Hydrocortisone
  • [Number-of-references] 40
  •  go-up   go-down


5. Gilat H, Cohen M, Feinmesser R, Benzion J, Shvero J, Segal K, Ulanovsky D, Shpitzer T: Minimally invasive procedure for resection of a parathyroid adenoma: the role of preoperative high-resolution ultrasonography. J Clin Ultrasound; 2005 Jul-Aug;33(6):283-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimally invasive procedure for resection of a parathyroid adenoma: the role of preoperative high-resolution ultrasonography.
  • PURPOSE: Solitary adenoma of the parathyroid is the major cause of primary hyperparathyroidism.
  • Many centers advocate a minimally invasive surgical approach, wherein the surgeon explores only a localized area of the neck according to the preoperative imaging evaluation, and the adenoma is resected without histological sampling from the other parathyroid glands.
  • The aim of this study was to evaluate the ability of high-resolution ultrasonography (US) to localize adenomas preoperatively and thereby aid in patient selection for minimal procedures.
  • METHODS: We reviewed the medical records of 77 consecutive patients who underwent resection of a parathyroid adenoma following ultrasonographic imaging between 2001 and 2002, and we assessed the accuracy of the preoperative localization of the adenomas as well as the efficacy of the minimally invasive procedure.
  • RESULTS: US correctly localized the adenoma to a specific quadrant of the neck in 87% of the cases and to a specific side of the neck in 94%.
  • Its sensitivity was not reduced by the presence of nodular disease of the thyroid gland.
  • CONCLUSIONS: US performed by a skilled operator is a reliable tool for adenoma localization prior to minimally invasive parathyroidectomy.
  • If there is a high clinical suspicion of adenoma in the presence of negative imaging studies, bilateral neck exploration should be performed.
  • [MeSH-major] Adenoma / surgery. Minimally Invasive Surgical Procedures / methods. Parathyroid Glands / ultrasonography. Parathyroid Neoplasms / surgery. Preoperative Care / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16134156.001).
  • [ISSN] 0091-2751
  • [Journal-full-title] Journal of clinical ultrasound : JCU
  • [ISO-abbreviation] J Clin Ultrasound
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Takashima K, Ito Y, Gonzalez FJ, Nakajima T: Different mechanisms of DEHP-induced hepatocellular adenoma tumorigenesis in wild-type and Ppar alpha-null mice. J Occup Health; 2008;50(2):169-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different mechanisms of DEHP-induced hepatocellular adenoma tumorigenesis in wild-type and Ppar alpha-null mice.
  • A recent study revealed that long-term exposure to relatively low-dose DEHP (0.05%) caused liver tumors including hepatocellular carcinomas, hepatocellular adenomas, and chologiocellular carcinomas at a higher incidence in Ppar alpha-null mice (25.8%) than in wild-type mice (10.0%).
  • Using tissues with hepatocellular adenoma, microarray (Affymetrix MOE430A) as well as, in part, real-time quantitative PCR analysis was conducted to elucidate the mechanisms of the adenoma formation resulting from DEHP exposure in both genotyped mice.
  • The microarray profiles showed that the up- or down-regulated genes were quite different between hepatocellular adenoma tissues of wild-type and Ppar alpha-null mice exposed to DEHP.
  • The gene expressions of apoptotic peptidase activating factor 1 (Apaf1) and DNA-damage-inducible 45 alpha (Gadd45a) were increased in the hepatocellular adenoma tissues of wild-type mice exposed to DEHP, whereas they were unchanged in corresponding tissues of Ppar alpha-null mice.
  • On the other hand, the expressions of cyclin B2 and myeloid cell leukemia sequence 1 were increased only in the hepatocellular adenoma tissues of Ppar alpha-null mice.
  • Taken together, DEHP may induce hepatocellular adenomas, in part, via suppression of G2/M arrest regulated by Gadd45a and caspase 3-dependent apoptosis in Ppar alpha-null mice, but these genes may not be involved in tumorigenesis in the wild-type mice.
  • In contrast, the expression level of Met was notably increased in the liver adenoma tissue of wild-type mice, which may suggest the involvement of Met in DEHP-induced tumorigenesis in wild-type mice.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BIS(2-ETHYLHEXYL) PHTHALATE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18403868.001).
  • [ISSN] 1348-9585
  • [Journal-full-title] Journal of occupational health
  • [ISO-abbreviation] J Occup Health
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Apaf1 protein, mouse; 0 / Apoptotic Protease-Activating Factor 1; 0 / Cell Cycle Proteins; 0 / Gadd45a protein, mouse; 0 / Nuclear Proteins; 0 / PPAR alpha; 0 / Plasticizers; 0 / RNA, Messenger; C42K0PH13C / Diethylhexyl Phthalate; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


7. Malur PR, Suranagi VV, Bannur HB, Kulgod S: Serous microcystic adenoma of the pancreas. Indian J Pathol Microbiol; 2009 Jul-Sep;52(3):408-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous microcystic adenoma of the pancreas.
  • Serous microcystic adenoma (SMA) is a rare benign neoplasm.
  • It is important to identify SMAs and distinguish them from mucinous cystic neoplasm, which can be premalignant or malignant, and pseudocyst, which is a non neoplastic condition.
  • [MeSH-major] Adenoma / diagnosis. Adenoma / pathology. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19679977.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


8. Folker MB, Bernstein IT, Holck S: [Serrated, hyperplastic and hyperplasia-like colorectal polyps]. Ugeskr Laeger; 2006 Nov 13;168(46):4005-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The colorectal hyperplastic polyp has generally been considered a finding of no clinical significance.
  • The term "advanced serrated polyp" has been coined for such cases, which comprise mixed hyperplastic/adenomatous tissue, serrated adenoma, and sessile serrated polyp, in contrast to the traditional hyperplastic polyp.
  • Since epithelial dysplasia is an integrated component of mixed hyperplastic/adenomatous polyp and of the serrated adenoma, such a diagnosis would dictate control colonoscopy comparable to the guidelines for subjects with conventional adenomas.
  • The cytology of the sessile serrated polyp is, however, closer to that of the traditional hyperplastic polyp, whereas the architecture mimics that of the serrated adenoma.
  • [MeSH-major] Adenoma / pathology. Colonic Polyps / pathology. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17125655.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 40
  •  go-up   go-down


9. Stern MC, Siegmund KD, Corral R, Haile RW: XRCC1 and XRCC3 polymorphisms and their role as effect modifiers of unsaturated fatty acids and antioxidant intake on colorectal adenomas risk. Cancer Epidemiol Biomarkers Prev; 2005 Mar;14(3):609-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] XRCC1 and XRCC3 polymorphisms and their role as effect modifiers of unsaturated fatty acids and antioxidant intake on colorectal adenomas risk.
  • Using a large sigmoidoscopy-based case-control study (753 cases and 799 controls) in Los Angeles County, we investigated possible associations between single-nucleotide polymorphisms in the XRCC1 (codons 194 Arg/Trp and codon 399 Arg/Gln) and XRCC3 (codon 241 Thr/Met) genes and colorectal adenoma risk and their possible role as modifiers of the effect of monounsaturated fatty acid, the ratio of omega-6/omega-3 polyunsaturated fatty acids, and antioxidant intake.
  • Subjects with the XRCC1 Gln/Gln genotype were inversely associated with adenoma risk (odds ratio, 0.6; 95% confidence interval, 0.4-0.9; P = 0.01) when compared with subjects with Arg/Arg and Arg/Gln genotypes combined.
  • High monounsaturated fatty acid intake was associated with adenoma risk only among subjects with the XRCC1 codon 194 Arg/Arg and codon 399 Gln/Gln combined genotypes (P for interaction = 0.018).
  • High omega-6/omega-3 polyunsaturated fatty acid ratios were associated with adenoma risk among subjects with the XRCC1 codon 194 Arg/Arg and codon 399 Gln/Gln or the codon 194 Arg/Trp or Trp/Trp and codon 399 Arg/Arg or Arg/Gln combined genotypes (P for interaction = 0.026).
  • Our data suggest that the XRCC1 codon 194 and codon 399 single nucleotide polymorphisms may modify the effect of unsaturated fatty acid and antioxidant intake and that this XRCC1 effect modification may explain, in part, previously reported inconsistencies on the role of unsaturated fatty acids and adenoma risk.
  • [MeSH-major] Adenoma / etiology. Adenoma / genetics. Antioxidants / pharmacology. Colorectal Neoplasms / etiology. Colorectal Neoplasms / genetics. DNA-Binding Proteins / genetics. Dietary Fats, Unsaturated / pharmacology. Polymorphism, Genetic

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15767338.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1R01CA096830
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / DNA-Binding Proteins; 0 / Dietary Fats, Unsaturated; 0 / X-ray repair cross complementing protein 1; 0 / X-ray repair cross complementing protein 3
  •  go-up   go-down


10. Oikarinen SI, Pajari AM, Salminen I, Heinonen SM, Adlercreutz H, Mutanen M: Effects of a flaxseed mixture and plant oils rich in alpha-linolenic acid on the adenoma formation in multiple intestinal neoplasia (Min) mice. Br J Nutr; 2005 Oct;94(4):510-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of a flaxseed mixture and plant oils rich in alpha-linolenic acid on the adenoma formation in multiple intestinal neoplasia (Min) mice.
  • To study the effects of a flaxseed mixture on adenoma formation in multiple intestinal neoplasia mice, the mice were fed a diet containing 2.7 % flaxseed, 4.5 % fibre and 3.7 % ALA.
  • The median number of adenomas in the small intestine was fifty-four for the control group, and thirty-seven (P=0.023) and forty-two (P=0.095) for flaxseed and oil groups, respectively.
  • Compared with controls (1.2 mm), the adenoma size was smaller in the flaxseed (0.9 mm; P=0.002) and oil (1.0 mm; P=0.012) groups.
  • Both diets changed the proportions of n-3 and n-6 fatty acids in the colonic mucosa.
  • Membrane beta-catenin and protein kinase C (PKC)-zeta levels were reduced in the adenoma v. mucosa (P<0.05), and an inverse association was found between the membrane PKC-zeta in the mucosa and the adenoma number (r -0.460, P=0.008, n 32).
  • [MeSH-major] Adenoma / prevention & control. Flax. Intestinal Neoplasms / prevention & control. Neoplasms, Multiple Primary / prevention & control. Plant Oils / administration & dosage. alpha-Linolenic Acid / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LINSEED OIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16197574.001).
  • [ISSN] 0007-1145
  • [Journal-full-title] The British journal of nutrition
  • [ISO-abbreviation] Br. J. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / Fatty Acids; 0 / Lignans; 0 / Plant Oils; 0 / beta Catenin; 0RBV727H71 / alpha-Linolenic Acid; 8001-26-1 / Linseed Oil; EC 1.14.99.1 / Cyclooxygenase 2; EC 2.7.11.13 / Protein Kinase C
  •  go-up   go-down


11. Xiao P, Xue L, Peng JJ, Feng ST, Liao B, Wen JM: An intrasellar mixed gangliocytoma-adenoma including ependymal component, and review of the literature. BMJ Case Rep; 2009;2009
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An intrasellar mixed gangliocytoma-adenoma including ependymal component, and review of the literature.
  • A rare case of intrasellar mixed gangliocytoma-adenoma including ependymal component, which presented clinically with acromegaly and menstrual disorder, is described here.
  • A histological examination of the resected specimen showed that the tumour was composed of ganglion cells, adenomatous cells and ependymal cells.
  • Most intrasellar gangliocytomas are composed of two components: adenomatous cells and ganglion cells.
  • In this case, in addition to mixed adenomatous and ganglion cells, focal ependymal cells forming small cysts were found.
  • Based on these histopathological findings, it was inferred that stem cells existed in the pituitary gland during embryonic development.
  • The stem cells were able to differentiate into three directions: ganglion cells, adenomatous cells and ependymal cells, and as a result an intrasellar mixed gangliocyto-adenoma including ependymal component developed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):607-13 [10757410.001]
  • [Cites] Brain Pathol. 2002 Jul;12(3):391-2, 397 [12146807.001]
  • [Cites] Acta Neuropathol. 2002 Oct;104(4):435-40 [12200632.001]
  • [Cites] Arch Pathol Lab Med. 2005 Mar;129(3):415-6 [15737044.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4240-5 [8633048.001]
  • [Cites] Minim Invasive Neurosurg. 1997 Sep;40(3):107-9 [9359090.001]
  • [Cites] Neurosurgery. 1997 Mar;40(3):611-4; discussion 614-5 [9055303.001]
  • [Cites] Brain Tumor Pathol. 2002;19(2):63-7 [12622135.001]
  • [Cites] J Endocrinol Invest. 2005 Feb;28(2):162-5 [15887863.001]
  • [Cites] Acta Neuropathol. 2006 Jul;112(1):21-8 [16699777.001]
  • [Cites] Hum Pathol. 1989 Dec;20(12):1198-203 [2591950.001]
  • [Cites] Ultrastruct Pathol. 1994 Nov-Dec;18(6):565-74 [7855931.001]
  • [Cites] Virchows Arch. 1994;425(1):93-9 [7921420.001]
  • [Cites] Neurosurgery. 1993 Nov;33(5):920-4; discussion 924-5 [8264895.001]
  • (PMID = 21686419.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3029532
  •  go-up   go-down


12. Pohl J, Lotterer E, Balzer C, Sackmann M, Schmidt KD, Gossner L, Schaab C, Frieling T, Medve M, Mayer G, Nguyen-Tat M, Ell C: Computed virtual chromoendoscopy versus standard colonoscopy with targeted indigocarmine chromoscopy: a randomised multicentre trial. Gut; 2009 Jan;58(1):73-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed virtual chromoendoscopy with the Fujinon intelligent colour enhancement (FICE) system is a new dyeless imaging technique that might allow higher rates of adenoma detection.
  • In total, 236 adenomas (mean of 0.64 per case) were detected in the FICE group and 271 adenomas (mean of 0.68 per case) in the control group (p = 0.92).
  • There was no statistically significant difference in the percentage of patients with >or=1 adenoma between the control group (35.4%) and the FICE group (35.6%) (p = 1.0).
  • For the differential diagnosis of adenomas and non-neoplastic polyps, the sensitivity of FICE (92.7%) was comparable with that of indigocarmine (90.4%) (p = 0.44).
  • CONCLUSIONS: At colonoscopy, adenoma detection rates are not improved by virtual chromoendoscopy with the FICE system compared with white light endoscopy with targeted indigocarmine spraying.
  • [MeSH-major] Adenoma / diagnosis. Colonoscopy / methods. Colorectal Neoplasms / diagnosis


13. Augoff K, Rabczynski J, Tabola R, Czapla L, Ratajczak K, Grabowski K: Immunohistochemical study of decorin expression in polyps and carcinomas of the colon. Med Sci Monit; 2008 Oct;14(10):CR530-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Recent studies showed that a small leucine-rich proteoglycan, decorin, may suppress tumor progression as a natural anticancer agent negatively controlling cellular growth.
  • It was hypothesized that physiological expression of decorin may be associated with cellular senescence of the colorectal mucosa and that its down-regulation, promoting an increase in cellular proliferation, could participate in the progression of adenoma to adenocarcinoma.
  • MATERIAL/METHODS: Tissue samples were obtained from 41 patients with different types of colonic polyps (6 hyperplastic adenomas, 34 neoplastic adenomas, and 1 adenomatous polyp with focal carcinoma) and 12 patients with colon cancer.
  • RESULTS: Normal and hyperplastic tissues and the majority of tubular adenomas showed strong expression of decorin in the stroma.
  • Adenomas with a villous component showed moderate and very low decorin immunoreactivity.
  • The decrease in decorin reactivity in tubulo-villous adenomas was significant as compared with other polyps and controls.

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18830193.001).
  • [ISSN] 1643-3750
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / DCN protein, human; 0 / Decorin; 0 / Extracellular Matrix Proteins; 0 / Proteoglycans
  •  go-up   go-down


14. Arber N, Levin B: Chemoprevention of colorectal neoplasia: the potential for personalized medicine. Gastroenterology; 2008 Apr;134(4):1224-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoprevention of colorectal neoplasia: the potential for personalized medicine.
  • The poor survival rate of advanced CRC has prompted the emphasis on prevention of this disease.
  • CRC screening and removal of adenomas is an effective intervention, and is the cornerstone of prevention.
  • Chemoprevention involves the long-term use of a variety of oral agents that can delay, prevent or even reverse the development of adenomas in the large bowel, thus interfering with the multi-step progessing from adenoma to carcinoma.
  • This effect is of particular importance to individuals with a hereditary prediposition to colorectal neoplasia and to those who are especially susceptile to the environmental causes of CRC.
  • Sulindac and celecoxib are effective in promoting poly regression in high risk individuals with Familial Adenomatous Polyposis (FAP).
  • In the more common sporadic setting the APROVe (refecoxib), APC and PreSAP (Celecoxib) trials have shown a significant reduction in adenoma recurrence but important concerns exist regarding cardiovascular toxicity associated with selective COX-2 inhibitors.
  • These landmark studies are very important, as they provide a proof of concept that we can prevent high risk adenomas that can lead to CRC development.


15. Zheng HC, Takahashi H, Li XH, Hara T, Masuda S, Guan YF, Takano Y: Downregulated parafibromin expression is a promising marker for pathogenesis, invasion, metastasis and prognosis of gastric carcinomas. Virchows Arch; 2008 Feb;452(2):147-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To clarify the roles of parafibromin expression in tumourigenesis and progression of gastric carcinomas, it was examined by immunohistochemistry (IHC) on tissue microarray containing gastric carcinomas (n = 508), adenomas (n = 45) and gastritis (n = 49) with a comparison of its expression with clinicopathological parametres of carcinomas.
  • Parafibromin expression was localised in the nucleus of gastric epithelial cells, adenoma, carcinoma cells and cell lines.
  • Its expression was gradually decreased from gastritis to gastric carcinoma, through gastric adenomas (p < 0.05) and inversely correlated with tumour size, depth of invasion, lymphatic invasion, lymph node metastasis and Union Internationale Contre le Cancer (UICC) staging (p < 0.05) but not with sex or venous invasion (p > 0.05).
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Stomach Neoplasms / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Blotting, Western. Cell Line, Tumor. Cell Nucleus / metabolism. Down-Regulation. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Prognosis. Survival Rate. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Genet. 2003 Sep;40(9):657-63 [12960210.001]
  • [Cites] Pathol Int. 2003 Oct;53(10):659-66 [14516315.001]
  • [Cites] N Engl J Med. 2003 Oct 30;349(18):1722-9 [14585940.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1141-9 [15167936.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6629-37 [15475453.001]
  • [Cites] Naika. 1967 Nov;20(5):824-9 [4877774.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 1992 Sep-Oct;11(5-6):339-44 [1464819.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Mol Cell Biol. 2005 Jan;25(2):612-20 [15632063.001]
  • [Cites] Oncogene. 2005 Feb 10;24(7):1272-6 [15580289.001]
  • [Cites] Mol Cell Biol. 2005 Jun;25(12):5052-60 [15923622.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Apr;134(4):481-8 [17876606.001]
  • [Cites] J Med Genet. 2005 Aug;42(8):e51 [16061557.001]
  • [Cites] Horm Metab Res. 2005 Jun;37(6):380-3 [16001331.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Feb;101(2):212-8 [16448924.001]
  • [Cites] Cell. 2006 Apr 21;125(2):327-41 [16630820.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):509-23 [16728578.001]
  • [Cites] Oral Oncol. 2006 Aug;42(7):735-9 [16458039.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1140-9 [16931959.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Nov 10;350(1):17-24 [16989776.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Dec;132(12):817-23 [16807756.001]
  • [Cites] Br J Cancer. 2006 Nov 20;95(10):1371-8 [17088917.001]
  • [Cites] J Anat. 2006 Dec;209(6):817-27 [17118068.001]
  • [Cites] Mol Cancer Res. 2007 Feb;5(2):183-93 [17314275.001]
  • [Cites] Oncogene. 2007 Feb 22;26(8):1213-21 [16964291.001]
  • [Cites] J Clin Pathol. 2007 Mar;60(3):273-7 [16714395.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Dec;15(4):432-40 [18091387.001]
  • [Cites] J Clin Pathol. 2008 Jan;61(1):64-7 [17468290.001]
  • [Cites] Mol Cell. 2003 Jan;11(1):267-74 [12535539.001]
  • [Cites] Nat Genet. 2002 Dec;32(4):676-80 [12434154.001]
  • [Cites] Mol Cell. 2003 Mar;11(3):721-9 [12667454.001]
  • [Cites] J Clin Epidemiol. 2003 Jan;56(1):1-9 [12589864.001]
  • [Cites] Oncogene. 2005 Sep 15;24(41):6241-8 [16116486.001]
  • (PMID = 18080135.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDC73 protein, human; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2233709
  •  go-up   go-down


16. van der Windt DJ, Kok NF, Hussain SM, Zondervan PE, Alwayn IP, de Man RA, IJzermans JN: Case-orientated approach to the management of hepatocellular adenoma. Br J Surg; 2006 Dec;93(12):1495-502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case-orientated approach to the management of hepatocellular adenoma.
  • BACKGROUND: Treatment of suspected hepatocellular adenoma (HA) remains controversial.
  • CONCLUSION: Observation of adenomas smaller than 5 cm is justified because of improved radiological reliability.
  • [MeSH-major] Adenoma, Liver Cell / diagnosis. Liver Neoplasms / diagnosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17051603.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contraceptives, Oral
  •  go-up   go-down


17. Nakayama Y, Inoue H, Hamada Y, Takeshita M, Iwasaki H, Maeshiro K, Iwanaga S, Tani H, Ryu S, Yasunami Y, Ikeda S: Intraductal tubular adenoma of the pancreas, pyloric gland type: a clinicopathologic and immunohistochemical study of 6 cases. Am J Surg Pathol; 2005 May;29(5):607-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal tubular adenoma of the pancreas, pyloric gland type: a clinicopathologic and immunohistochemical study of 6 cases.
  • The intraductal tubular adenoma (ITA), pyloric gland type, of the pancreas is an uncommon benign tumor, akin to the pyloric gland type adenoma of the gallbladder.
  • In 2 cases, the adjacent pancreas showed foci of intraductal papillary-mucinous adenoma.
  • All patients are alive with no evidence of disease 3 to 10.5 years after surgical resection.
  • [MeSH-major] Adenoma / pathology. Gastric Mucosa / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. DNA-Binding Proteins / analysis. Epithelial Cells / pathology. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Mucins / analysis. Mucins / classification. Pancreaticoduodenectomy. Pepsinogen A / analysis. Smad4 Protein. Trans-Activators / analysis. Treatment Outcome. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832084.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Mucins; 0 / SMAD4 protein, human; 0 / Smad4 Protein; 0 / Trans-Activators; 0 / Tumor Suppressor Protein p53; 9001-10-9 / Pepsinogen A
  •  go-up   go-down


18. Schroy PC 3rd, Glick JT, Wilson S, Robinson PA, Heeren TC: An effective educational strategy for improving knowledge, risk perception, and risk communication among colorectal adenoma patients. J Clin Gastroenterol; 2008 Jul;42(6):708-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An effective educational strategy for improving knowledge, risk perception, and risk communication among colorectal adenoma patients.
  • BACKGROUND: We have previously shown that most adenoma patients are unaware of the personal and familial implications of their diagnosis.
  • METHODS: Using a quasi-randomized design, adenoma-bearing subjects were assigned to the CBEP +PL (n=99), CBEP (n=96), or SC (n=120) arms.
  • Subjects in the CBEP+PL group were more likely (P<0.05) than those in the SC group to know that adenomas but not hyperplastic polyps were precancerous, that patients with adenomas were at increased risk of future adenomas, and that the siblings and children of adenoma patients may be at increased colorectal cancer risk.
  • Subjects in the CBEP+PL group were also more likely (P<0.05) to know their polyp's histology, perceive themselves and their siblings/children to be at increased risk of colorectal neoplasia, and notify a first-degree relative.
  • CONCLUSIONS: The CBEP+PL intervention is an effective strategy for improving knowledge, risk perception, and risk communication among adenoma patients.
  • [MeSH-major] Adenomatous Polyps / psychology. Colorectal Neoplasms / psychology. Health Knowledge, Attitudes, Practice. Patient Education as Topic / methods

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18574393.001).
  • [ISSN] 1539-2031
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K22-CA90680
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


19. Robertson DJ, Sandler RS, Haile R, Tosteson TD, Greenberg ER, Grau M, Baron JA: Fat, fiber, meat and the risk of colorectal adenomas. Am J Gastroenterol; 2005 Dec;100(12):2789-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fat, fiber, meat and the risk of colorectal adenomas.
  • OBJECTIVE: The aim of this study was to determine the relationship between fat, fiber, and meat intake, and risk of colorectal adenoma recurrence.
  • METHODS: We determined adenoma recurrence and dietary intake for 1,520 participants in two randomized trials: The Antioxidant Polyp Prevention Study and Calcium Polyp Prevention Study.
  • Subjects underwent baseline colonoscopy with removal of all adenomas, and dietary intake was estimated with a validated semiquantitative food frequency questionnaire.
  • Pooled risk ratios for adenoma recurrence were obtained by generalized linear regression, with adjustment for age, sex, clinical center, treatment category, study, and duration of observation.
  • RESULTS: In the total colorectum, fiber intake was weakly and nonsignificantly associated with a risk for all adenomas (RR quartile 4 vs quartile 1=0.85, 95% CI 0.69-1.05) and advanced adenomas (RR=0.88, 95% CI 0.54-1.44).
  • Associations were stronger for adenomas in the proximal colon (RR=0.73, 95% CI 0.56-0.97) and some fiber subtypes (fruit and vegetable, grain).
  • There was no association between fat or total red meat intake and risk of adenoma or advanced adenoma recurrence.
  • However, when considering other meats, risk (quartile 4 vs quartile 1) for advanced adenoma was increased for processed meat (RR=1.75, 95% CI 1.02-2.99) and decreased for chicken (RR=0.61, 95% CI 0.38-0.98).
  • CONCLUSION: The inverse associations between fiber intake and risk of adenoma recurrence we observed are weak, and not statistically significant.
  • [MeSH-major] Adenoma / therapy. Colorectal Neoplasms / therapy. Diet. Dietary Fats / adverse effects. Dietary Fiber / administration & dosage. Neoplasm Recurrence, Local / prevention & control

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • MedlinePlus Health Information. consumer health - Dietary Fiber.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16393237.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA23108; United States / NCI NIH HHS / CA / CA46927
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dietary Fats
  •  go-up   go-down


20. Díaz R, Frisancho O, Palomino A: [Adenoma of the Brunner's glands: a case report]. Rev Gastroenterol Peru; 2008 Jul-Sep;28(3):274-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenoma of the Brunner's glands: a case report].
  • The histological study of the specimen revealed a Brunner's glands tumor.
  • The Brunner's glands tumor, also known as brunneroma, is a rare benign duodenum's lesion; it could be incidentally discover during an endoscopy and sometimes it cause of bleeding or obstruction.
  • There is controversy if this tumor is an hamartoma or a true adenoma.
  • [MeSH-major] Adenoma. Brunner Glands. Duodenal Neoplasms

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18958145.001).
  • [ISSN] 1022-5129
  • [Journal-full-title] Revista de gastroenterología del Perú : órgano oficial de la Sociedad de Gastroenterología del Perú
  • [ISO-abbreviation] Rev Gastroenterol Peru
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Peru
  •  go-up   go-down


21. Kim S, Keku TO, Martin C, Galanko J, Woosley JT, Schroeder JC, Satia JA, Halabi S, Sandler RS: Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res; 2008 Jan 1;68(1):323-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating levels of inflammatory cytokines and risk of colorectal adenomas.
  • The association between obesity and colorectal neoplasia may be mediated by inflammation.
  • Circulating levels of C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) are elevated in the obese.
  • We examined circulating levels of CRP, IL-6, and TNF-alpha in relation to risk factors and the prevalence of colorectal adenomas.
  • Plasma levels of CRP, IL-6, and TNF-alpha were quantified in 873 participants (242 colorectal adenoma cases and 631 controls) in a colonoscopy-based cross-sectional study conducted between 1998 and 2002.
  • Multivariable logistic regression was used to estimate associations between known risk factors for colorectal neoplasia and circulating levels of inflammatory cytokines and associations between inflammatory cytokines and colorectal adenomas.
  • Several known risk factors for colorectal neoplasia were associated with higher levels of inflammatory cytokines, including older age, current smoking, and increasing adiposity.
  • The prevalence of colorectal adenomas was associated with higher concentrations of IL-6 and TNF-alpha and, to a lesser degree, with CRP.
  • For IL-6, adjusted odds ratios (OR) for colorectal adenomas were 1.79 [95% confidence interval (CI), 1.19-2.69] for the second highest plasma level and 1.85 (95% CI, 1.24-2.75) for the highest level compared with the reference level.
  • Our findings indicate that systemic inflammation might be involved in the early development of colorectal neoplasia.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2003 Apr 9;289(14):1799-804 [12684358.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1126-31 [16775170.001]
  • [Cites] J Clin Invest. 2003 Dec;112(12):1796-808 [14679176.001]
  • [Cites] JAMA. 2004 Feb 4;291(5):585-90 [14762037.001]
  • [Cites] Nat Rev Cancer. 2004 Aug;4(8):579-91 [15286738.001]
  • [Cites] Obes Res. 2004 Jul;12(7):1094-103 [15292473.001]
  • [Cites] Annu Rev Med. 2000;51:245-70 [10774463.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]
  • [Cites] Clin Chem. 2001 Mar;47(3):426-30 [11238292.001]
  • [Cites] J Am Coll Cardiol. 2001 Jun 15;37(8):2036-41 [11419884.001]
  • [Cites] Proc Nutr Soc. 2001 Aug;60(3):329-39 [11681807.001]
  • [Cites] Am J Epidemiol. 2001 Dec 15;154(12):1089-99 [11744511.001]
  • [Cites] Nutrition. 2001 Nov-Dec;17(11-12):953-66 [11744348.001]
  • [Cites] Am J Epidemiol. 2002 Jan 15;155(2):176-84 [11790682.001]
  • [Cites] Am J Cardiol. 2002 May 1;89(9):1117-9 [11988205.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2002 Oct 1;22(10):1668-73 [12377747.001]
  • [Cites] J Pathol. 2002 Dec;198(4):428-34 [12434411.001]
  • [Cites] Br J Nutr. 2004 Sep;92(3):347-55 [15469638.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2004 Sep;59(9):M924-9 [15472157.001]
  • [Cites] Proc Natl Acad Sci U S A. 1975 Sep;72(9):3666-70 [1103152.001]
  • [Cites] Am J Epidemiol. 1986 Sep;124(3):453-69 [3740045.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2182-91 [9215292.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1997 Oct;17(10):2167-76 [9351386.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4601-6 [9539784.001]
  • [Cites] Circulation. 1999 Aug 24;100(8):793-8 [10458713.001]
  • [Cites] J Biol Chem. 2004 Nov 19;279(47):48487-90 [15337754.001]
  • [Cites] Nutr Rev. 2005 Jan;63(1):22-8 [15730232.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2294-9 [15572589.001]
  • [Cites] Ann Intern Med. 2005 Mar 15;142(6):425-32 [15767620.001]
  • [Cites] Cancer Cell. 2005 Mar;7(3):211-7 [15766659.001]
  • [Cites] J Allergy Clin Immunol. 2005 May;115(5):911-9; quiz 920 [15867843.001]
  • [Cites] J Epidemiol. 2005 Jun;15 Suppl 2:S185-9 [16127232.001]
  • [Cites] Psychosom Med. 2005 Sep-Oct;67(5):679-87 [16204423.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2413-8 [16214925.001]
  • [Cites] Nat Rev Cancer. 2006 Jan;6(1):24-37 [16397525.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2483-7 [16489056.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):690-5 [16614110.001]
  • [Cites] Mech Ageing Dev. 2003 Apr;124(4):487-93 [12714257.001]
  • (PMID = 18172326.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA044684; United States / NCI NIH HHS / CA / R01 CA044684-17; United States / NCI NIH HHS / CA / R01 CA 44684; United States / NIDDK NIH HHS / DK / P30 DK034987; United States / NCI NIH HHS / CA / CA044684-17; United States / NIDDK NIH HHS / DK / P30 DK034987-23; United States / NIDDK NIH HHS / DK / P30 DK34987
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha
  • [Other-IDs] NLM/ NIHMS92897; NLM/ PMC2675825
  •  go-up   go-down


22. Peris M, Espinàs JA, Muñoz L, Navarro M, Binefa G, Borràs JM, Catalan Colorectal Cancer Screening Pilot Programme Group: Lessons learnt from a population-based pilot programme for colorectal cancer screening in Catalonia (Spain). J Med Screen; 2007;14(2):81-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY OBJECTIVE: To assess the feasibility of a colorectal cancer population-based screening programme in Catalonia (Spain).
  • In the first round, the prevalence of screen-detected cancer was 2.1 per 1000 screened people, 7.2 for high-risk adenomas (HRA) and 11.3 for neoplasm (cancer and/or adenoma).
  • The positive predictive value (PPV) was 6.2% for cancer, 21.2% for HRA and 33.3% for advanced neoplasm.
  • In the second round, the prevalence of screen-detected cancer was 0.9 per 1000 people screened, 2.8 per 1000 for HRA and 4.2 per 1000 for neoplasm.
  • The PPV was 10.6% for cancer, 34.1% for HRA and 50.4% for any neoplasm.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17626707.001).
  • [ISSN] 0969-1413
  • [Journal-full-title] Journal of medical screening
  • [ISO-abbreviation] J Med Screen
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


23. Katori H, Nozawa A, Tsukuda M: Expression of epidermal growth factor receptor, transforming growth factor-alpha and Ki-67 in relationship to malignant transformation of pleomorphic adenoma. Acta Otolaryngol; 2007 Nov;127(11):1207-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of epidermal growth factor receptor, transforming growth factor-alpha and Ki-67 in relationship to malignant transformation of pleomorphic adenoma.
  • The data support the hypothesis that increased epidermal growth factor receptor (EGFR) and transforming growth factor (TGF)-alpha expression is associated with early events in malignant transformation of pleomorphic adenoma (PA).
  • OBJECTIVE: In the present study, we attempted to identify EGFR and TGF-alpha expression and Ki-67 index in carcinoma ex-pleomorphic adenoma (Ca ex-PA) and PA.
  • RESULTS: As regards the association of patients' prognosis with EGFR staining and Ki-67 index, a significant increase was observed in patients who died or had residual disease compared with patients who were alive without disease.
  • [MeSH-major] Adenoma, Pleomorphic / metabolism. Biomarkers, Tumor / biosynthesis. Cell Transformation, Neoplastic. Ki-67 Antigen / genetics. Receptor, Epidermal Growth Factor / biosynthesis. Salivary Gland Neoplasms / metabolism. Transforming Growth Factor alpha / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17851915.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Transforming Growth Factor alpha; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


24. Cetani F, Pardi E, Banti C, Collecchi P, Viacava P, Borsari S, Fanelli G, Naccarato AG, Saponaro F, Berti P, Miccoli P, Pinchera A, Marcocci C: Beta-catenin activation is not involved in sporadic parathyroid carcinomas and adenomas. Endocr Relat Cancer; 2010 Mar;17(1):1-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beta-catenin activation is not involved in sporadic parathyroid carcinomas and adenomas.
  • The aim of this study was to evaluate whether Wnt/beta-catenin signaling is activated in parathyroid carcinomas and adenomas.
  • We studied 154 parathyroid tumors (18 carcinomas (13 with distant metastases), six atypical adenomas, and 130 adenomas).
  • Immunostaining of beta-catenin was performed in all carcinomas and in 66 adenomas (including three atypical).
  • With the exception of one carcinoma, which had a negative membrane staining, all other samples showed a membrane staining which was similar to that of the normal parathyroid. beta-Catenin expression was heterogeneous with a range of positive cells between 5 and 80%, independently of tumor type.
  • Our results suggest that the Wnt/beta-catenin signaling pathway is not involved in the development of parathyroid carcinomas and adenomas.
  • [MeSH-major] Adenoma / physiopathology. Carcinoma / physiopathology. Neoplasm Proteins / physiology. Parathyroid Neoplasms / physiopathology. Signal Transduction / physiology. Wnt Proteins / physiology. beta Catenin / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755524.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / Wnt Proteins; 0 / beta Catenin
  •  go-up   go-down


25. Sharon E, Kelly RJ, Szabo E: Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine. Head Neck Oncol; 2010;2:12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine.
  • BACKGROUND: Carcinoma ex pleomorphic adenoma is a rare histologic subtype of salivary gland cancer with an overall poor prognosis.
  • We report here a case of a 58-year old man with metastatic carcinoma ex pleomorphic adenoma who achieved a sustained long term response to combination therapy with trastuzumab and capecitabine.
  • CASE PRESENTATION: A 58 year old man presented with T1N2bM0 carcinoma ex pleomorphic adenoma and underwent surgery followed by adjuvant radiation therapy.
  • Since the original tumor was strongly HER2/neu positive by immunohistochemistry, the patient was treated with trastuzumab, capecitabine, and zoledronic acid.
  • He experienced total resolution of symptoms and repeat FDG-PET scan after three cycles revealed interval disease resolution.
  • Continued treatment has resulted in maintenance of disease control for over 2 years.
  • CONCLUSION: This case illustrates the successful long term treatment of carcinoma ex pleomorphic adenoma with targeted therapy with trastuzumab in combination with chemotherapy.
  • In the absence of definitive clinical trials which are unlikely to be performed due to the rarity of this tumor, case reports such as this one suggest potential utility for trastuzumab in combination with chemotherapy in the treatment of HER2/neu-overexpressing carcinoma ex pleomorphic adenoma.
  • [MeSH-major] Adenoma, Pleomorphic / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Salivary Gland Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3246-50 [17577021.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3978-84 [17761983.001]
  • [Cites] Head Neck. 2008 May;30(5):680-3 [17972317.001]
  • [Cites] Semin Oncol. 2008 Jun;35(3):309-19 [18544445.001]
  • [Cites] J Laryngol Otol. 2009 Feb;123(2):250-2 [18405406.001]
  • [Cites] Laryngoscope. 1992 Aug;102(8):923-7 [1353853.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):596-604 [11431714.001]
  • [Cites] Head Neck. 2001 Sep;23(9):705-12 [11505478.001]
  • [Cites] Oral Oncol. 2002 Oct;38(7):706-13 [12167424.001]
  • [Cites] Oral Oncol. 2003 Oct;39(7):724-7 [12907212.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2673-8 [16763282.001]
  • (PMID = 20504363.001).
  • [ISSN] 1758-3284
  • [Journal-full-title] Head & neck oncology
  • [ISO-abbreviation] Head Neck Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2889991
  •  go-up   go-down


26. Triggiani V, Guastamacchia E, Lolli I, Troccoli G, Resta F, Sabbà C, Ruggieri N, Tafaro E: Association of a wide invasive malignant thymoma with myastenia gravis and primary hyperparathyroidism due to parathyroid adenoma: case report and review of the literature. Immunopharmacol Immunotoxicol; 2006;28(2):377-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of a wide invasive malignant thymoma with myastenia gravis and primary hyperparathyroidism due to parathyroid adenoma: case report and review of the literature.
  • In these cases the hyperparathyroidism was due to the presence of an adenoma or hyperplasic parathyroid tissue either in the cervical region or in an ectopic intrathymic location.(12345) In other cases the syndrome of hypercalcemia was due to the secretion of parathyroid-related protein (PTHRP) (6) or parathyroid hormone (PTH) (7) by the thymoma itself.
  • We report the first case, at the best of our knowledge, of a wide invasive malignant thymoma (type B3), associated with myasthenia gravis and hyperparathyroidism caused by parathyroid adenoma.
  • [MeSH-major] Adenoma / pathology. Hyperparathyroidism, Primary / pathology. Myasthenia Gravis / pathology. Parathyroid Neoplasms / pathology. Thymus Neoplasms / pathology


27. Yerli H, Aydin E, Haberal N, Harman A, Kaskati T, Alibek S: Diagnosing common parotid tumours with magnetic resonance imaging including diffusion-weighted imaging vs fine-needle aspiration cytology: a comparative study. Dentomaxillofac Radiol; 2010 Sep;39(6):349-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: masses comprised eight Warthin tumours, eight adenomas (six pleomorphic adenomas, two basal cell adenomas), five carcinomas, two lipomas, one haemagioma and one benign lymphadenopathy.
  • Diagnostic accuracy did not increase by adding DWI to conventional MRI; however, DWI was helpful for diagnosing benign tumour histology.
  • MRI combined with DWI was successful for determining accurate tumour typing in all benign masses except one lymphadenopathy.
  • CONCLUSIONS: MRI combined with DWI seems to have similar diagnostic potential as FNAC in differentiation of benign vs malignant parotid masses.
  • [MeSH-major] Adenolymphoma / pathology. Adenoma / pathology. Biopsy, Fine-Needle. Carcinoma / pathology. Diffusion Magnetic Resonance Imaging. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1999 Nov;35(5):432-8 [10583558.001]
  • [Cites] Radiology. 2000 Jul;216(1):19-29 [10887223.001]
  • [Cites] Radiology. 2001 Sep;220(3):621-30 [11526259.001]
  • [Cites] Laryngoscope. 2001 Nov;111(11 Pt 1):1989-92 [11801984.001]
  • [Cites] AJR Am J Roentgenol. 2002 Apr;178(4):959-65 [11906883.001]
  • [Cites] Clin Radiol. 2002 Aug;57(8):692-701 [12169280.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Aug;25(7):1256-62 [15313720.001]
  • [Cites] Radiology. 1989 Dec;173(3):823-6 [2813793.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Mar;17(3):555-9 [8881252.001]
  • [Cites] Head Neck. 1999 Jan;21(1):43-51 [9890350.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 May;26(5):1201-6 [15891184.001]
  • [Cites] Ann Acad Med Singapore. 2006 Apr;35(4):242-8 [16710494.001]
  • [Cites] AJNR Am J Neuroradiol. 2007 Jan;28(1):116-21 [17213436.001]
  • [Cites] Acad Radiol. 2007 Jun;14(6):701-10 [17502260.001]
  • [Cites] Acta Radiol. 2007 Nov;48(9):980-7 [17957512.001]
  • [Cites] AJNR Am J Neuroradiol. 2009 Mar;30(3):591-6 [19131405.001]
  • (PMID = 20729184.001).
  • [ISSN] 0250-832X
  • [Journal-full-title] Dento maxillo facial radiology
  • [ISO-abbreviation] Dentomaxillofac Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3520240
  •  go-up   go-down


28. Shindo ML, Rosenthal JM: Minimal access parathyroidectomy using the focused lateral approach: technique, indication, and results. Arch Otolaryngol Head Neck Surg; 2007 Dec;133(12):1227-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MAIN OUTCOME MEASURES: The FLA was used when preoperative sestamibi single-photon emission computed tomography or ultrasonography showed an adenoma located superiorly, posteriorly, or retroesophageally.
  • Intraoperative rapid parathyroid hormone assay was used to confirm a single adenoma in all cases.
  • The FLA improves the mean excision time for excision of posteriorly located parathyroid adenomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18086964.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Lawrance AK, Deng L, Rozen R: Methylenetetrahydrofolate reductase deficiency and low dietary folate reduce tumorigenesis in Apc min/+ mice. Gut; 2009 Jun;58(6):805-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To determine if Mthfr deficiency and low dietary folate influence tumorigenesis in mice genetically predisposed to form numerous intestinal adenomas (Apc(min/+)).
  • RESULTS: Apc(min/+) mice fed high folate diets from weaning developed more adenomas than those fed the folic acid-deficient diet (FADD) or the control diet (CD); Mthfr deficiency did not affect adenoma number.
  • However, when the FADD and CD were administered to dams prior to conception, throughout pregnancy and continued in offspring post-weaning, Apc(min/+) offspring fed FADD developed fewer adenomas than those fed CD.
  • Mthfr(+/-) genotype of the mother or of the offspring also reduced adenoma numbers in the Apc(min/+) offspring.
  • Adenoma number was inversely correlated with plasma homocysteine (r = -0.49, p<0.005, intestinal dUTP/dTTP ratios (r = -0.42, p = 0.05), and levels of intestinal apoptosis (r = -0.36, p = 0.08).
  • CONCLUSIONS: Low dietary folate and Mthfr deficiency reduce adenoma formation in mice predisposed to tumorigenesis, possibly through increased apoptosis consequent to hyperhomocysteinaemia and nucleotide imbalances.
  • [MeSH-major] Adenoma / pathology. Adenomatous Polyposis Coli Protein / genetics. Colorectal Neoplasms / pathology. Diet. Folic Acid / administration & dosage. Methylenetetrahydrofolate Reductase (NADPH2) / deficiency
  • [MeSH-minor] Animals. Apoptosis. DNA Methylation. Female. Genetic Predisposition to Disease. Genotype. Homocysteine / blood. Male. Mice. Mice, Inbred C57BL. Mice, Mutant Strains. Pregnancy. Prenatal Nutritional Physiological Phenomena. Random Allocation. Thymine Nucleotides / analysis. Uridine Triphosphate / analysis. Weaning

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19174418.001).
  • [ISSN] 1468-3288
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Thymine Nucleotides; 0LVT1QZ0BA / Homocysteine; 935E97BOY8 / Folic Acid; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); QOP4K539MU / thymidine 5'-triphosphate; UT0S826Z60 / Uridine Triphosphate
  •  go-up   go-down


30. Matsuno A: [Recent trends in the pathophysiology and treatment of pituitary adenomas]. Brain Nerve; 2009 Aug;61(8):957-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recent trends in the pathophysiology and treatment of pituitary adenomas].
  • The patterns of cytodifferentiation are closely related to the pathogenesis of pituitary adenomas.
  • Meanwhile, the role of hypothalamic hormones in the development of pituitary adenomas has recently attracted the attention of investigators.
  • The expression of growth hormone-releasing hormone and corticotrophin releasing hormone in corticotroph adenomas have been demonstrated in somatotroph adenomas and corticotropin adenomas, respectively.
  • This finding indicates that the endogenous expression of hypothalamic hormones and their receptors in human pituitary adenoma cells has ample significance in the autocrine or paracrine regulation of pituitary hormone production and tumor extension induced by hypothalamic hormones produced by adenoma cells.
  • The recent progress in surgical techniques for treatment of pituitary adenomas has provided several alternatives: transsphenoidal surgery vs. transcranial surgery, sublabial approach vs. endonasal approach, and microsurgery vs. endoscopic surgery.
  • There have also been developments in the medical treatment of pituitary adenomas.
  • The frequently used dopamine agonist, cabergoline, is very effective for treating prolactin-producing adenoma.
  • Long-acting octreotide and pegvisomant are now available for the treatment of growth hormone producing adenoma.
  • Cabergoline is also used for growth hormone producing adenoma.
  • Temozolomide has recently been used for atypical adenomas or pituitary carcinomas.
  • Adult growth hormone deficiency sometimes occurs in postoperative patients with pituitary adenomas.
  • [MeSH-major] Adenoma / etiology. Adenoma / therapy. Pituitary Neoplasms / etiology. Pituitary Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697885.001).
  • [ISSN] 1881-6096
  • [Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo
  • [ISO-abbreviation] Brain Nerve
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ergolines; 0 / Hypothalamic Hormones; 0 / Receptors, Neuropeptide; 0 / Receptors, Pituitary Hormone-Regulating Hormone; 0 / pegvisomant; 0 / somatotropin releasing hormone receptor; 12629-01-5 / Human Growth Hormone; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 9015-71-8 / Corticotropin-Releasing Hormone; 9034-39-3 / Growth Hormone-Releasing Hormone; LL60K9J05T / cabergoline; RWM8CCW8GP / Octreotide
  • [Number-of-references] 32
  •  go-up   go-down


31. Huang L, Wang X, Gong W, Huang Y, Jiang B: The comparison of the clinical manifestations and risk factors of colorectal cancer and adenomas: results from a colonoscopy-based study in southern Chinese. Int J Colorectal Dis; 2010 Nov;25(11):1343-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The comparison of the clinical manifestations and risk factors of colorectal cancer and adenomas: results from a colonoscopy-based study in southern Chinese.
  • This study aimed to compare the clinical manifestations and risk factors of CRC and adenomas in native patients of Guangzhou.
  • Data on demographic information, main clinical manifestations, results of endoscopies and pathology, and possible risk factors of colorectal tumor were collected.
  • Chi-square test and logistic regression were used to compare the clinical characteristics and risk factors for CRC and adenomas.
  • Older age [odds ratio (OR), 1.079; 95% confidence interval (CI), 1.065-1.093], smoking status (OR, 1.712; 95% CI, 1.158-2.531), BMI =18.5-24.9 and  ≥ 25.0 (OR, 2.384; 95% CI, 1.250-4.549; OR, 2.162; 95% CI, 1.044-4.478, respectively) were significant risk factors for advanced adenoma, while female (OR, 0.638; 95% CI, 0.429-0.949) and using aspirin (OR, 0.188; 95% CI, 0.042-0.845) were significant protective factors.
  • For southern Chinese the most important influential factors for colorectal tumor are age, smoking, drinking, nutritional state, DM, hypertension, and the use of aspirin.
  • [MeSH-major] Adenoma / pathology. Asian Continental Ancestry Group. Colonoscopy. Colorectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Obes (Lond). 2008 Feb;32(2):304-14 [17878894.001]
  • [Cites] Am J Gastroenterol. 1996 Feb;91(2):287-91 [8607494.001]
  • [Cites] Br J Surg. 2002 Jul;89(7):845-60 [12081733.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):28-36 [16721800.001]
  • [Cites] Lancet. 2003 May 3;361(9368):1496-501 [12737858.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2007 Jul 24;87(28):1950-3 [17923029.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):385-91 [11927499.001]
  • [Cites] Cancer. 1996 Sep 15;78(6):1187-94 [8826939.001]
  • [Cites] Dis Colon Rectum. 2008 Jan;51(1):56-61 [18030529.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Aug;7(8):661-6 [9718217.001]
  • [Cites] Public Health Nutr. 2006 Sep;9(6):755-62 [16925881.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):526-31 [17372248.001]
  • [Cites] Am J Epidemiol. 1998 Jul 1 ;148(1):4-16 [9663397.001]
  • [Cites] Am J Gastroenterol. 2003 Dec;98(12):2777-83 [14687832.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):883-90 [12621132.001]
  • [Cites] Cancer Detect Prev. 2008;32(1):33-8 [18400417.001]
  • [Cites] J Natl Cancer Inst. 1997 Oct 1;89(19):1406-22 [9326910.001]
  • [Cites] World J Gastroenterol. 2009 Nov 7;15(41):5141-8 [19891012.001]
  • [Cites] Cancer Causes Control. 1996 Mar;7(2):253-63 [8740738.001]
  • [Cites] J Natl Cancer Inst. 2007 Nov 21;99(22):1729-35 [18000222.001]
  • [Cites] Lancet. 2007 May 12;369(9573):1603-13 [17499602.001]
  • [Cites] Br J Cancer. 2004 Jun 1;90(11):2157-66 [15150609.001]
  • [Cites] Zhonghua Liu Xing Bing Xue Za Zhi. 2004 Mar;25(3):265-8 [15200945.001]
  • [Cites] Ann Med. 1994 Dec;26(6):443-52 [7695871.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):937-41 [11535544.001]
  • [Cites] Clin Gastroenterol Hepatol. 2003 Mar;1(2):96-102 [15017501.001]
  • [Cites] Gastroenterology. 2007 Oct;133(4):1077-85 [17698067.001]
  • [Cites] Int J Cancer. 2006 Aug 1;119(3):630-5 [16496385.001]
  • [Cites] Lancet Oncol. 2005 Nov;6(11):871-6 [16257795.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):1183-8 [7926468.001]
  • [Cites] Jpn J Cancer Res. 1999 Aug;90(8):805-11 [10543250.001]
  • [Cites] Dis Colon Rectum. 1999 Mar;42(3):337-42 [10223753.001]
  • [Cites] JAMA. 2005 Aug 24;294(8):914-23 [16118381.001]
  • [Cites] Br J Cancer. 1998;77(1):174-9 [9459165.001]
  • [Cites] Med Sci Sports Exerc. 2008 Feb;40(2):303-7 [18202571.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2391-7 [17164361.001]
  • [Cites] Cancer Causes Control. 1994 May;5(3):215-20 [8061168.001]
  • [Cites] J Am Coll Cardiol. 2007 Nov 20;50(21):2085-92 [18021879.001]
  • [Cites] World J Gastroenterol. 2003 Nov;9(11):2400-3 [14606064.001]
  • [Cites] N Engl J Med. 1996 Jan 11;334(2):82-7 [8531963.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):622-9 [12101109.001]
  • [Cites] Cancer Causes Control. 2003 Nov;14(9):879-87 [14682445.001]
  • [Cites] Am J Epidemiol. 1998 Apr 1;147(7):670-80 [9554606.001]
  • [Cites] Annu Rev Nutr. 1999;19:545-86 [10448536.001]
  • [Cites] Med Sci Sports Exerc. 2003 Aug;35(8):1381-95 [12900694.001]
  • [Cites] Gastroenterology. 2008 Feb;134(2):617-9 [18242224.001]
  • [Cites] JAMA. 2007 Sep 26;298(12):1412-9 [17895457.001]
  • [Cites] Eur J Cancer Prev. 2007 Apr;16(2):102-7 [17297385.001]
  • [Cites] Nutr Cancer. 2001;39(1):50-7 [11588902.001]
  • [Cites] Ann Epidemiol. 1993 May;3(3):239-44 [8275195.001]
  • [Cites] JAMA. 2005 Jul 6;294(1):47-55 [15998890.001]
  • [Cites] N Engl J Med. 2005 May 19;352(20):2061-8 [15901859.001]
  • (PMID = 20680303.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


32. Tijhuis MJ, Wark PA, Aarts JM, Visker MH, Nagengast FM, Kok FJ, Kampman E: GSTP1 and GSTA1 polymorphisms interact with cruciferous vegetable intake in colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev; 2005 Dec;14(12):2943-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GSTP1 and GSTA1 polymorphisms interact with cruciferous vegetable intake in colorectal adenoma risk.
  • The possible interplay between cruciferous vegetable consumption, functional genetic variations in glutathione S-transferases (GST) M1, T1, P1, and A1, and colorectal adenomas, was investigated in a Dutch case-control study.
  • The GSTM1 and GSTT1 deletion polymorphisms, and the single nucleotide polymorphisms in GSTP1 (A313G) and in GSTA1 (C-69T) were assessed among 746 cases who developed colorectal adenomas and 698 endoscopy-based controls without any type of colorectal polyps.
  • High consumption was slightly positively associated with colorectal adenomas [odds ratio (OR) 1.15; 95% confidence interval, 0.92-1.44].
  • The GSTM1 and GSTT1 genotypes did not seem to modify the association between cruciferous vegetable intake and colorectal adenomas.
  • In conclusion, GSTP1 and GSTA1 genotypes might modulate the association between cruciferous vegetable intake and colorectal adenomas.
  • [MeSH-major] Adenoma / enzymology. Adenoma / genetics. Colorectal Neoplasms / enzymology. Colorectal Neoplasms / genetics. Glutathione S-Transferase pi / genetics. Glutathione Transferase / genetics. Polymorphism, Genetic. Vegetables
  • [MeSH-minor] Biomarkers, Tumor / genetics. Case-Control Studies. Chi-Square Distribution. Female. Humans. Logistic Models. Male. Middle Aged. Netherlands. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16365014.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.5.1.18 / Glutathione Transferase
  •  go-up   go-down


33. Costa-Nogueira C, Villar-Portela S, Cuevas E, Gil-Martín E, Fernández-Briera A: Synthesis and expression of CDw75 antigen in human colorectal cancer. BMC Cancer; 2009;9:431
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By immunohistochemistry we assessed the CDw75 expression in 25 colorectal adenomas, 43 tumours, 13 transitional and 28 healthy tissues of CRC patients.
  • CDw75 expression was positive in 20% of colorectal adenomas.
  • CONCLUSION: The major contribution of this study is the inclusion of data from transitional tissue and the analysis of CDw75 antigen expression in CRC and in colorectal adenomas, little known so far.
  • The expression of CDw75 in colorectal adenomas suggests that this antigen may be a tumour marker in CRC.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Antigens, CD / biosynthesis. Antigens, CD / metabolism. Biomarkers, Tumor / analysis. Colorectal Neoplasms / metabolism. Sialyltransferases / biosynthesis. Sialyltransferases / metabolism
  • [MeSH-minor] Aged. Disease Progression. Gene Expression. Humans. Immunohistochemistry. Neoplasm Staging

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2000 Mar;46(3):359-66 [10673297.001]
  • [Cites] Glycobiology. 2006 Feb;16(2):146-54 [16192407.001]
  • [Cites] Hybridoma. 2000 Aug;19(4):281-6 [11001400.001]
  • [Cites] J Pathol. 2001 Feb;193(2):169-74 [11180162.001]
  • [Cites] Eur J Biochem. 2001 Nov;268(22):5876-84 [11722575.001]
  • [Cites] J Biol Chem. 2002 Nov 29;277(48):45719-28 [12235148.001]
  • [Cites] Pathol Oncol Res. 2002;8(3):175-82 [12515997.001]
  • [Cites] Eur J Biochem. 2003 Mar;270(5):950-61 [12603328.001]
  • [Cites] Oncogene. 2003 Oct 16;22(46):7137-45 [14562042.001]
  • [Cites] World J Gastroenterol. 2004 Jun 1;10(11):1682-5 [15162552.001]
  • [Cites] Eur J Biochem. 2004 Sep;271(18):3623-34 [15355339.001]
  • [Cites] Nature. 1982 Nov 18;300(5889):274-6 [7144883.001]
  • [Cites] Anal Biochem. 1985 Oct;150(1):76-85 [3843705.001]
  • [Cites] J Biol Chem. 1987 Feb 5;262(4):1596-601 [3805045.001]
  • [Cites] Int J Cancer. 1989 Sep 15;44(3):434-9 [2476402.001]
  • [Cites] Dis Colon Rectum. 1990 Jun;33(6):498-501 [2351004.001]
  • [Cites] J Biol Chem. 1991 Aug 25;266(24):15984-91 [1714903.001]
  • [Cites] J Biol Chem. 1991 Nov 15;266(32):21674-80 [1657976.001]
  • [Cites] Am J Pathol. 1991 Dec;139(6):1435-48 [1661075.001]
  • [Cites] Cancer Res. 1992 Apr 1;52(7):1775-9 [1312899.001]
  • [Cites] Eur J Biochem. 1993 Jan 15;211(1-2):135-40 [7678804.001]
  • [Cites] Arch Biochem Biophys. 1993 Jun;303(2):255-9 [8512312.001]
  • [Cites] Cancer. 1993 Sep 1;72(5):1522-7 [8348485.001]
  • [Cites] Cancer Lett. 1993 Dec 20;75(3):143-9 [8313349.001]
  • [Cites] Clin Sci (Lond). 1995 Oct;89(4):397-404 [7493440.001]
  • [Cites] Glycoconj J. 1996 Feb;13(1):115-21 [8785482.001]
  • [Cites] FASEB J. 1997 Mar;11(4):248-55 [9068613.001]
  • [Cites] J Surg Oncol. 1998 Feb;67(2):85-9 [9486778.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):243-7 [10188726.001]
  • [Cites] Biochem J. 1961 Nov;81:384-92 [13860975.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4645-52 [15930282.001]
  • [Cites] Oncology. 2005;69(5):436-44 [16319516.001]
  • [Cites] Int J Cancer. 2000 Oct 1;88(1):58-65 [10962440.001]
  • (PMID = 20003255.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; EC 2.4.99.- / Sialyltransferases; EC 2.4.99.1 / ST6GAL1 protein, human
  • [Other-IDs] NLM/ PMC2803195
  •  go-up   go-down


34. Xu Q, Yuan X, Tunici P, Liu G, Fan X, Xu M, Hu J, Hwang JY, Farkas DL, Black KL, Yu JS: Isolation of tumour stem-like cells from benign tumours. Br J Cancer; 2009 Jul 21;101(2):303-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolation of tumour stem-like cells from benign tumours.
  • We set out to test whether tumour stem-like cells can be identified from benign tumours.
  • METHODS: Tumour sphere cultures were derived from hormone-positive and -negative pituitary adenomas.
  • RESULTS: In this study, we isolated sphere-forming, self-renewable, and multipotent stem-like cells from pituitary adenomas, which are benign tumours.
  • We found that pituitary adenoma stem-like cells (PASCs), compared with their differentiated daughter cells, expressed increased levels of stem cell-associated gene products, antiapoptotic proteins, and pituitary progenitor cell markers.
  • CONCLUSION: This study for the first time indicates that stem-like cells are present in benign tumours.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2003 Dec;112(11):1603-18 [14660734.001]
  • [Cites] Nature. 2003 May 15;423(6937):255-60 [12714970.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Sep;75 Suppl 3:iii47-52 [15316045.001]
  • [Cites] Curr Opin Genet Dev. 2004 Oct;14(5):567-74 [15380249.001]
  • [Cites] Mol Endocrinol. 1994 Jul;8(7):878-85 [7527122.001]
  • [Cites] Annu Rev Med. 1996;47:95-106 [8712806.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Oncogene. 2004 Dec 16;23(58):9392-400 [15558011.001]
  • [Cites] J Endocrinol. 2005 Jan;184(1):41-50 [15642781.001]
  • [Cites] Mol Endocrinol. 2005 Apr;19(4):964-71 [15637144.001]
  • [Cites] Endocrinology. 2005 May;146(5):2376-87 [15677762.001]
  • [Cites] Mol Endocrinol. 2005 May;19(5):1383-91 [15677710.001]
  • [Cites] J Neurosci Res. 2005 May 15;80(4):456-66 [15795928.001]
  • [Cites] Exp Cell Res. 2005 Aug 1;308(1):166-76 [15916758.001]
  • [Cites] J Clin Pharmacol. 2005 Aug;45(8):872-7 [16027397.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):650-3 [18385740.001]
  • [Cites] Breast Cancer Res. 2008;10(1):R10 [18241344.001]
  • [Cites] Breast Cancer Res. 2008;10(2):105 [18423071.001]
  • [Cites] J Clin Invest. 2008 Jun;118(6):2111-20 [18497886.001]
  • [Cites] Neuroscience. 2008 Jun 23;154(2):541-50 [18462887.001]
  • [Cites] Nature. 2008 Dec 4;456(7222):593-8 [19052619.001]
  • [Cites] Stem Cells. 2008 Dec;26(12):3018-26 [18787206.001]
  • [Cites] Endocrinology. 2005 Sep;146(9):3985-98 [15932930.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Glia. 2006 Feb;53(3):294-303 [16265670.001]
  • [Cites] Clin Adv Hematol Oncol. 2006 Jan;4(1):63-72 [16562373.001]
  • [Cites] Cancer Cell. 2006 May;9(5):391-403 [16697959.001]
  • [Cites] Genes Dev. 2006 Oct 1;20(19):2739-53 [17015435.001]
  • [Cites] Stem Cells. 2006 Nov;24(11):2382-90 [16857898.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Mol Cancer. 2006;5:67 [17140455.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Neuroendocrinology. 2007;85(2):110-30 [17337880.001]
  • [Cites] Physiol Rev. 2007 Jul;87(3):933-63 [17615393.001]
  • [Cites] Science. 2007 Jul 20;317(5836):337 [17641192.001]
  • [Cites] Cell. 2007 Dec 14;131(6):1109-23 [18083101.001]
  • [Cites] Dev Neurosci. 2000;22(1-2):139-53 [10657706.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):1180-7 [10720059.001]
  • [Cites] Mod Pathol. 2001 Sep;14(9):892-9 [11557786.001]
  • [Cites] Clin Neurosurg. 2001;48:306-19 [11692649.001]
  • [Cites] Science. 2002 Mar 22;295(5563):2231-5 [11910101.001]
  • [Cites] Ultrastruct Pathol. 2002 Jul-Aug;26(4):219-28 [12227947.001]
  • [Cites] Exp Neurol. 2002 Dec;178(2):288-93 [12504887.001]
  • [Cites] Pituitary. 2002;5(2):89-98 [12675506.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):285-95 [15057288.001]
  • (PMID = 19568241.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS048959-04; United States / NINDS NIH HHS / NS / R01 NS048959; United States / NINDS NIH HHS / NS / NS048959; United States / NINDS NIH HHS / NS / R01 NS048959-04; United States / NINDS NIH HHS / NS / R56 NS048959; United States / NINDS NIH HHS / NS / R21 NS048879-02; United States / NINDS NIH HHS / NS / NS048879-02; United States / NINDS NIH HHS / NS / R21 NS048879; United States / NINDS NIH HHS / NS / NS048879
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hypothalamic Hormones; 0 / Pituitary Hormones
  • [Other-IDs] NLM/ PMC2720199
  •  go-up   go-down


35. Leman ES, Schoen RE, Magheli A, Sokoll LJ, Chan DW, Getzenberg RH: Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer. Clin Cancer Res; 2008 Mar 1;14(5):1349-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 111 serum samples from individuals who underwent colonoscopy and were subsequently diagnosed as either being normal or having hyperplastic polyps, nonadvanced adenomas, advanced adenomas, and colorectal cancer were evaluated.
  • CCSA-2 at a cutoff of 10.8 mug/mL has overall specificity of 78.4% [95% confidence interval (95% CI), 67.3-87.1%] and sensitivity of 97.3% (95% CI, 85.8-99.5%) in separating individuals with advanced adenomas and colorectal cancer from normal, hyperplastic, and nonadvanced adenoma populations.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionIn] Schoen RE, Magheli A, Sokoll LJ, Chan DW, Getzenberg RH. Clin Cancer Res. 2013 Jan 15;19(2):508 [23271798.001]
  • (PMID = 18316554.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA084968; United States / NCI NIH HHS / CA / U01 CA084968-01; United States / NCI NIH HHS / CA / CA084968
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Retracted Publication
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / colon cancer-specific antigen 2, human; 0 / colon-specific antigen
  • [Other-IDs] NLM/ NIHMS371863; NLM/ PMC4664476
  •  go-up   go-down


36. de Maat MF, Umetani N, Sunami E, Turner RR, Hoon DS: Assessment of methylation events during colorectal tumor progression by absolute quantitative analysis of methylated alleles. Mol Cancer Res; 2007 May;5(5):461-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of methylation events during colorectal tumor progression by absolute quantitative analysis of methylated alleles.
  • To study, in detail, methylation during colorectal cancer development in high-risk adenomas, we developed an assay combining in situ (on-slide) sodium bisulfite modification (SBM) of paraffin-embedded archival tissue sections with absolute quantitative assessment of methylated alleles (AQAMA).
  • AQAMA assays were used to measure methylation levels at MINT (methylated in tumor) loci MINT1, MINT2, MINT12, and MINT31.
  • Methylation levels of adenomatous and cancerous components within a single tissue section in 72 colorectal cancer patients were analyzed.
  • Methylation levels at the four loci increased in 11% and decreased in 36% of specimens comparing paired adenoma and cancer tissues (P<0.0001 by Kolmogorov-Smirnov test).
  • Variable MINT locus methylation level changes occur during malignant progression of colorectal adenoma.
  • [MeSH-minor] Base Sequence. Cell Line, Tumor. DNA Mutational Analysis. Disease Progression. Humans. Molecular Sequence Data. Nerve Tissue Proteins / genetics. Nerve Tissue Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17510312.001).
  • [ISSN] 1541-7786
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins
  •  go-up   go-down


37. Hubina E, Nanzer AM, Hanson MR, Ciccarelli E, Losa M, Gaia D, Papotti M, Terreni MR, Khalaf S, Jordan S, Czirják S, Hanzély Z, Nagy GM, Góth MI, Grossman AB, Korbonits M: Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur J Endocrinol; 2006 Aug;155(2):371-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Somatostatin (SST) analogues play an important role in the medical management of somatotroph pituitary adenomas and new agonists have the potential to be effective in a wider group of pituitary and other tumours.
  • METHODS: Human pituitary adenoma cells and rat pituitary cell line (GH3) were cultured and treated in vitro with octreotide and the broad-spectrum SST agonist SOM230 (pasireotide).
  • RESULTS: We detected upregulation of p27 protein levels with SST analogue treatment in vitro in human pituitary adenoma samples. pERK1/2 was inhibited by SST analogues in both the human samples and GH3 cells.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. TRITIUM, RADIOACTIVE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16868153.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 10028-17-8 / Tritium; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; 51110-01-1 / Somatostatin; 98H1T17066 / pasireotide; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; RWM8CCW8GP / Octreotide; VC2W18DGKR / Thymidine
  •  go-up   go-down


38. Takahashi T, Miki Y, Takahashi JA, Kanagaki M, Yamamoto A, Fushimi Y, Okada T, Haque TL, Hashimoto N, Konishi J, Togashi K: Ectopic posterior pituitary high signal in preoperative and postoperative macroadenomas: dynamic MR imaging. Eur J Radiol; 2005 Jul;55(1):84-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Areas of enhanced hyperintensity were considered true PPHS, and the relationship between presence and location of true PPHS and adenoma volume was analyzed.
  • Adenoma volume was significantly greater for Group B than for Group A (p<0.001).
  • CONCLUSIONS: Greater volume of adenoma is associated with a higher incidence of ectopic PPHS, and the ectopic change is irreversible.
  • [MeSH-major] Adenoma / pathology. Magnetic Resonance Imaging / methods. Pituitary Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Analysis of Variance. Contrast Media. Female. Gadolinium DTPA. Humans. Image Processing, Computer-Assisted. Male. Middle Aged. Pituitary Gland, Posterior / pathology. Prospective Studies

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15950103.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media; 84F6U3J2R6 / gadodiamide; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


39. Metzler M, Luedecke DK, Saeger W, Grueters A, Haberl H, Kiess W, Repp R, Rascher W, Doetsch J: Low prevalence of Gs alpha mutations in śomatotroph adenomas of children and adolescents. Cancer Genet Cytogenet; 2006 Apr 15;166(2):146-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low prevalence of Gs alpha mutations in śomatotroph adenomas of children and adolescents.
  • Mutations in the gene coding for the alpha-subunit of the heterotrimeric stimulatory G protein Gs are the most frequently identified molecular events in the development of somatotroph adenomas in adults.
  • In children and adolescents, somatotroph adenomas are rare, and only two cases with the Gs alpha mutation have been reported so far.
  • In this study, we therefore investigated the prevalence of activating Gs alpha mutations in 17 patients younger than 20 years with pituitary growth hormone-secreting adenomas and examined the characteristics of mutation-positive cases.
  • Interestingly, in contrast to the remaining cases, the adenomas positive for the Gs alpha mutation proved to be nonsporadic, but part of a syndrome associated with endocrine tumors in both individuals.
  • Additional tests confirmed McCune-Albright syndrome in the first patient and multiple endocrine neoplasia type 1 syndrome in the second patient.
  • In contrast to the findings in adult cases, somatotroph adenomas in young patients seem to carry somatic Gs alpha mutations at a lower frequency, and germ-line or early postzygotic mutational events may be responsible for the shortened latency of tumorigenesis.
  • [MeSH-major] GTP-Binding Protein alpha Subunits, Gs / genetics. Growth Hormone-Secreting Pituitary Adenoma / genetics. Mutation / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16631471.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gs
  •  go-up   go-down


40. Kim JH, Kim JH, Han JH, Yoo BM, Kim MW, Kim WH: Is endoscopic papillectomy safe for ampullary adenomas with high-grade dysplasia? Ann Surg Oncol; 2009 Sep;16(9):2547-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is endoscopic papillectomy safe for ampullary adenomas with high-grade dysplasia?
  • OBJECTIVES: This study was designed to provide safe management guidelines for ampullary adenoma by analysis of clinicopathological features.
  • BACKGROUND: The treatment of ampullary cancer has been established; however, the indications for treatment of ampullary adenoma remain controversial.
  • METHODS: Between July 1997 and July 2008, a total of 33 patients were diagnosed with ampullary adenoma prior to procedures: 20 endoscopic papillectomies (ESP), 5 transduodenal resections (TDR), and 8 pancreatoduodenectomies (PD).
  • The size of tumor by final pathology was 1.27 +/- 0.89 cm in LGD, 1.81 +/- 0.99 cm in HGD, and 1.98 +/- 1.08 cm in cancer group.
  • There was a significant correlation between size of tumor and final pathology (P = 0.036).
  • According to receiver operating characteristic (ROC) curve, criterion to predict HGD/cancer was tumor size larger than 1.5 cm; sensitivity and specificity were 55.6% and 80.0%, respectively, and likelihood ratio was 2.778.
  • However, size of tumor was not associated with preprocedural pathology.
  • CONCLUSIONS: Ampullary adenoma with preprocedural HGD was highly associated with coexistence of cancer and recurrence.
  • Therefore, we suggest that ampullary adenoma with preprocedural HGD or more than 1.5 cm should not be managed with endoscopic papillectomy due to high associated rates of recurrence.
  • [MeSH-major] Adenoma / surgery. Ampulla of Vater / surgery. Common Bile Duct Neoplasms / surgery. Endoscopy, Gastrointestinal
  • [MeSH-minor] Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Pancreaticoduodenectomy. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19568817.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Torer N, Torun D, Torer N, Micozkadioglu H, Noyan T, Ozdemir FN, Haberal M: Predictors of early postoperative hypocalcemia in hemodialysis patients with secondary hyperparathyroidism. Transplant Proc; 2009 Nov;41(9):3642-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We recorded preoperative adjusted serum calcium (Ca(+2)), phosphate, alkaline phosphatase, intact parathyroid hormone, and hemoglobin levels; mean systolic and diastolic blood pressure levels; parathyroid ultrasonography and scintigraphic data; and number and weight of the resected adenomas.
  • Age (36.0 +/- 9.7 vs 49.2 +/- 16.6 years; P = .006); levels of preoperative serum Ca(+2) (9.6 +/- 0.7 vs 10.4 +/- 1.1 mg/dL; P = .01), alkaline phosphatase (346.7 +/- 354.7 vs 653.3 +/- 553.7 mg/dL; P = .05), and hemoglobin (10.5 +/- 1.4 vs 12.3 +/- 2.5 g/dL; P = .009); and number (2.0 +/- 1.3 vs 2.9 +/- 0.9; P = .04) and weight (1.9 +/- 2.1 vs 3.2 +/- 1.7; P = .01) of excised parathyroid adenomas were significantly lower among the hypocalcemia than the normocalcemia group.
  • Among hemodialysis patients with secondary hyperparathyroidism, age, levels of preoperative serum Ca(+2) and alkaline phosphatase, and number and weight of adenomas were associated with early development of postoperative hypocalcemia.

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19917359.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemoglobins; EC 3.1.3.1 / Alkaline Phosphatase; SY7Q814VUP / Calcium
  •  go-up   go-down


42. Iizuka H, Okamura S, Onozato Y, Ishihara H, Kakizaki S, Mori M: Endoscopic submucosal dissection for colorectal tumors. Gastroenterol Clin Biol; 2009 Oct-Nov;33(10-11):1004-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EMR was used in the majority of adenomas, and showed high rates of both one-piece resection (OPR) and complete resection (CR) for adenomas less than 20 mm.
  • However, for adenomas and cancers greater or equal to 20 mm, the CR rate for EMR was significantly lower than that for ESD because of the incidence of OPR with a positive lateral margin (16% vs 0% with ESD vs EMR).
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenoma / pathology. Adenoma / surgery. Adult. Aged. Aged, 80 and over. Female. Humans. Intestinal Perforation / etiology. Male. Middle Aged. Outcome Assessment (Health Care). Retrospective Studies. Risk Factors. Time Factors

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19762190.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] France
  •  go-up   go-down


43. Wang TD, Friedland S, Sahbaie P, Soetikno R, Hsiung PL, Liu JT, Crawford JM, Contag CH: Functional imaging of colonic mucosa with a fibered confocal microscope for real-time in vivo pathology. Clin Gastroenterol Hepatol; 2007 Nov;5(11):1300-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: Histologic interpretation of disease currently is performed with static images of excised tissues, and is limited by processing artifact, sampling error, and interpretive variability.
  • The aim of this study was to show the use of functional optical imaging of viable mucosa for quantitative evaluation of colonic neoplasia in real time.
  • RESULTS: Normal mucosa showed circular crypts with uniform size, hyperplasia revealed proliferative glands with serrated lumens, and adenomas displayed distorted elongated glands.
  • Passage of fluorescein through adenomatous mucosa was delayed substantially.
  • For t greater than 5 seconds, high sensitivity, specificity, and accuracy was achieved using a discriminant function to evaluate the contrast ratio to distinguish normal from lesional mucosa (91%, 87%, and 89%, respectively; P < .001), hyperplasia from adenoma (97%, 96%, and 96%, respectively; P < .001), and tubular from villous adenoma (100%, 92%, and 93%, respectively; P < .001).

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUORESCEIN .
  • Hazardous Substances Data Bank. D&C Yellow No. 8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Pharmacol. 2002 Jan 1;63(1):81-8 [11754877.001]
  • [Cites] Endoscopy. 2007 Feb;39 Suppl 1:E145 [17611888.001]
  • [Cites] Appl Opt. 2002 Jan 1;41(1):182-92 [11900434.001]
  • [Cites] Br J Nutr. 2003 May;89(5):639-47 [12720584.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6247-51 [15342411.001]
  • [Cites] Gastroenterology. 2004 Sep;127(3):706-13 [15362025.001]
  • [Cites] Hum Pathol. 1983 Nov;14(11):931-68 [6629368.001]
  • [Cites] Hum Pathol. 1988 Feb;19(2):166-78 [3343032.001]
  • [Cites] Appl Opt. 2004 Nov 1;43(31):5763-71 [15540433.001]
  • [Cites] J Vasc Res. 2004 Sep-Oct;41(5):400-11 [15467299.001]
  • [Cites] Gastroenterology. 2005 Jun;128(7):2119-23 [15940642.001]
  • [Cites] Gastrointest Endosc. 2005 Nov;62(5):686-95 [16246680.001]
  • [Cites] Cancer Immunol Immunother. 2006 Jan;55(1):47-55 [15868166.001]
  • [Cites] Radiology. 2006 Feb;238(2):405-22 [16436809.001]
  • [Cites] J Pharm Sci. 2006 Jun;95(6):1393-401 [16625653.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 May;4(5):566-72 [16630761.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):11003-8 [16835297.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Aug;4(8):979-87 [16843068.001]
  • [Cites] Biochem Pharmacol. 2006 Sep 14;72(6):729-38 [16844096.001]
  • [Cites] Endoscopy. 2006 Sep;38(9):886-90 [16981104.001]
  • [Cites] Nature. 2006 Oct 19;443(7113):765 [17051200.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Nov;4(11):1309-13 [17110299.001]
  • [Cites] Endoscopy. 2006 Nov;38(11):1110-4 [17111332.001]
  • [Cites] Neurosci Lett. 2007 Jan 3;411(1):1-5 [17110033.001]
  • [Cites] Am J Respir Crit Care Med. 2007 Jan 1;175(1):22-31 [17023733.001]
  • [Cites] Cell Tissue Res. 2007 Apr;328(1):77-84 [17165089.001]
  • [Cites] Gastrointest Endosc. 2007 Aug;66(2):398-99, discussion 400 [17521648.001]
  • [CommentIn] Clin Gastroenterol Hepatol. 2007 Nov;5(11):1259-60 [17936080.001]
  • (PMID = 17936692.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / K08 DK067618-04; United States / NIDDK NIH HHS / DK / K08 DK067618; United States / NCI NIH HHS / CA / U54 CA105296; United States / NIDDK NIH HHS / DK / K08 DK067618-05; United States / NIDDK NIH HHS / DK / DK067618-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; TPY09G7XIR / Fluorescein
  • [Other-IDs] NLM/ NIHMS34014; NLM/ PMC2104519
  •  go-up   go-down


44. Sansbury LB, Wanke K, Albert PS, Kahle L, Schatzkin A, Lanza E, Polyp Prevention Trial Study Group: The effect of strict adherence to a high-fiber, high-fruit and -vegetable, and low-fat eating pattern on adenoma recurrence. Am J Epidemiol; 2009 Sep 1;170(5):576-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of strict adherence to a high-fiber, high-fruit and -vegetable, and low-fat eating pattern on adenoma recurrence.
  • The authors examined the effect of strict adherence to a low-fat, high-fiber, high-fruit and -vegetable intervention over 4 years among participants (n = 1,905) in the US Polyp Prevention Trial (1991-1998) on colorectal adenoma recurrence.
  • Multivariate logistic regression models were used to estimate the association between dietary adherence and adenoma recurrence.
  • The authors observed a 35% reduced odds of adenoma recurrence among super compliers compared with controls (odds ratio = 0.65, 95% confidence interval: 0.47, 0.92).
  • Findings suggest that high compliance with a low-fat, high-fiber diet is associated with reduced risk of adenoma recurrence.
  • [MeSH-major] Adenoma / diet therapy. Colonic Neoplasms / diet therapy. Diet, Fat-Restricted. Dietary Fiber / administration & dosage. Neoplasm Recurrence, Local / prevention & control. Patient Compliance

  • MedlinePlus Health Information. consumer health - Dietary Fiber.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Apr 20;342(16):1149-55 [10770979.001]
  • [Cites] Eur J Clin Nutr. 2009 Jun;63(6):707-17 [18685556.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Sep;9(9):869-73 [11008902.001]
  • [Cites] Lancet. 2000 Oct 14;356(9238):1300-6 [11073017.001]
  • [Cites] Eur J Cancer Prev. 2000 Oct;9(5):363-5 [11075890.001]
  • [Cites] Gastroenterology. 2001 Feb;120(2):387-91 [11159879.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 4;93(7):525-33 [11287446.001]
  • [Cites] Am J Clin Nutr. 2001 Sep;74(3):387-401 [11522565.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2599-608 [12826634.001]
  • [Cites] Proc R Soc Med. 1971 Sep;64(9):964-5 [5114307.001]
  • [Cites] N Engl J Med. 1980 Oct 30;303(18):1038-41 [6999345.001]
  • [Cites] J Natl Cancer Inst. 1981 Jun;66(6):1191-308 [7017215.001]
  • [Cites] J Natl Cancer Inst. 1990 Apr 18;82(8):650-61 [2157027.001]
  • [Cites] J Clin Epidemiol. 1990;43(12):1327-35 [2254769.001]
  • [Cites] Stat Med. 1991 Oct;10(10):1595-605 [1947515.001]
  • [Cites] J Natl Cancer Inst. 1992 Dec 16;84(24):1887-96 [1334153.001]
  • [Cites] Stat Med. 1994 Nov 30;13(22):2323-35 [7855466.001]
  • [Cites] Ann Med. 1994 Dec;26(6):443-52 [7695871.001]
  • [Cites] J Clin Epidemiol. 1994 May;47(5):525-36 [7730878.001]
  • [Cites] J Natl Cancer Inst. 1995 Dec 6;87(23):1760-6 [7473832.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 May;5(5):375-83 [9162304.001]
  • [Cites] J Clin Pharmacol. 1997 Aug;37(8):667-72 [9378838.001]
  • [Cites] Cancer Causes Control. 1998 Aug;9(4):357-67 [9794167.001]
  • [Cites] Eur J Cancer Prev. 2005 Feb;14(1):21-9 [15677892.001]
  • [Cites] JAMA. 2006 Feb 8;295(6):643-54 [16467233.001]
  • [Cites] J Am Coll Nutr. 2006 Oct;25(5):370-81 [17031005.001]
  • [Cites] J Natl Cancer Inst. 2007 Oct 3;99(19):1471-83 [17895473.001]
  • [Cites] J Nutr. 2007 Nov;137(11):2443-50 [17951483.001]
  • [Cites] Cancer. 2007 Nov 15;110(10):2119-52 [17939129.001]
  • [Cites] Am J Epidemiol. 2008 Jul 1;168(1):38-48 [18525082.001]
  • [Cites] BMJ. 2008;337:a1344 [18786971.001]
  • [Cites] N Engl J Med. 2000 Apr 20;342(16):1156-62 [10770980.001]
  • (PMID = 19643809.001).
  • [ISSN] 1476-6256
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2732986
  • [Investigator] Schatzkin A; Lanza E; Corle D; Freedman LS; Clifford C; Tangrea J; Cooper MR; Paskett E; Quandt S; DeGraffinreid C; Bradham K; Kent L; Self M; Boyles D; West D; Martin L; Taylor N; Dickenson E; Kuhn P; Harmon J; Richardson I; Lee H; Marceau E; Lance MP; Marshal JR; Hayes D; Phillips J; Petrelli N; Shelton P; Randall E; Blake A; Wodarski L; Deinzer M; Melton R; Iber FL; Murphy P; Bote EC; Brandt-Whittington L; Haroon N; Kazi N; Moore MA; Orloff SB; Ottosen WJ; Patel M; Rothschild RL; Ryan M; Sullivan JM; Caan B; Selby JV; Friedman G; Lawson M; Taff G; Snow D; Belfay M; Schoenberger M; Sampel K; Giboney T; Randel M; Shike M; Winawer S; Bloch A; Mayer J; Morse R; Latkany L; D'Amato D; Schaffer A; Cohen L; Weissfeld J; Schoen R; Schade RR; Kuller L; Gahagan B; Caggiula A; Lucas C; Coyne T; Pappert S; Robinson R; Landis V; Misko S; Search L; Burt RW; Slattery M; Viscofsky N; Benson J; Neilson J; McDivitt R; Briley M; Heinrich K; Samowitz W; KikendalL JW; Mateski DJ; Wong R; Stoute E; Jones-Miskovsky V; Greaser A; Hancock S; Chandler S; Cahill J; Hasson M; Daston C; Brewer B; Zimmerman T; Sharbaugh C; O'Brien B; Cranston L; Odaka N; Umbel K; Pinsky J; Price H; Slonim A; Lewin K; Appelman H; Bachorik PS; Lovejoy K; Sowell A; Greenberg ER; Feldman E; Garza C; Summers R; Weiand S; DeMets D
  •  go-up   go-down


45. Ide F, Tanaka A, Kusama K: Further evidence for adipocytic differentiation by the neoplastic myoepithelium. J Oral Pathol Med; 2007 Mar;36(3):187-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lipomatous pleomorphic adenoma (PA)/myoepithelioma is rare.
  • Nevertheless, adipocytic differentiation in salivary gland tumors is a well-known phenomenon.
  • As extensive lipometaplasia occurs primarily in adenomas with myoepithelial participation, circumstantial evidence implicates neoplastic myoepithelium (NME), especially the spindle type, as a key partaker.
  • We report here a unique PA that represents an equivocal transition from the epithelioid NME to adipocytes in recurrent lesions but not in a primary tumor.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Adipocytes / pathology. Epithelial Cells / pathology. Myoepithelioma / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adult. Cell Differentiation. Humans. Male. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17305642.001).
  • [ISSN] 0904-2512
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


46. Hayashi S, Kitada M, Ozawa K, Sato K, Takamatsu M, Hirata S, Sasajima T: [Functional mediastinal parathyroid adenoma with cystic change; report of a case]. Kyobu Geka; 2010 Jul;63(7):599-601
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Functional mediastinal parathyroid adenoma with cystic change; report of a case].
  • We report a case of functional mediastinal parathyroid adenoma with cystic change.
  • Computed tomography (CT) revealed the shape of a cystic tumor with a diameter of 4 cm in the anterior mediastinum.
  • 99mTc-MIBI scintigraphy showed accumulation of the radioisotope in the tumor.
  • The patient was diagnosed as primary HPT caused by the cystic parathyroid adenoma.
  • The tumor was resected through a median sternotomy.
  • [MeSH-major] Adenoma / pathology. Parathyroid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20662244.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


47. Scarabin C, Koskas M, Bornes M, Azria E, Luton D: Gigantomastia and vulvar lactating adenoma in a patient with myasthenia during pregnancy. Am J Obstet Gynecol; 2010 Oct;203(4):e5-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gigantomastia and vulvar lactating adenoma in a patient with myasthenia during pregnancy.
  • We report the association of gigantomastia during pregnancy and a lactating adenoma in ectopic breast tissue of the vulva in a context of myasthenia in a 27-year-old primigravid woman.
  • [MeSH-major] Adenoma / diagnosis. Breast. Breast Diseases / diagnosis. Choristoma / diagnosis. Pregnancy Complications / diagnosis. Vulvar Diseases / diagnosis


48. Akin H, Gunluoglu Z, Kara V, Melek H, Dincer I: Mediastinal ectopic parathyroid adenoma: report of two cases successfully treated by VATS approach. Thorac Cardiovasc Surg; 2008 Feb;56(1):60-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal ectopic parathyroid adenoma: report of two cases successfully treated by VATS approach.
  • Ectopic parathyroid adenomas are the cause of approximately one in four cases of primary hyperparathyroidism (pHPT).
  • Most ectopic parathyroid adenomas are located adjacent to the upper thymus gland and can be resected with a collar incision.
  • In rare cases, however, adenomas located in the chest require a transsternalor transthoracic approach.
  • We present two cases with primary hyperparathyroidism due to mediastinal ectopic parathyroid adenoma that were successfully treated by VATS approach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18200473.001).
  • [ISSN] 0171-6425
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


49. Lupi I, Manetti L, Caturegli P, Menicagli M, Cosottini M, Iannelli A, Acerbi G, Bevilacqua G, Bogazzi F, Martino E: Tumor infiltrating lymphocytes but not serum pituitary antibodies are associated with poor clinical outcome after surgery in patients with pituitary adenoma. J Clin Endocrinol Metab; 2010 Jan;95(1):289-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor infiltrating lymphocytes but not serum pituitary antibodies are associated with poor clinical outcome after surgery in patients with pituitary adenoma.
  • CONTEXT: Serum pituitary antibodies (Pit Abs) and tumor-infiltrating lymphocytes (TILs) have been described in pituitary adenomas, but their clinical significance remains unknown.
  • OBJECTIVE: The objective of the study was to assess Pit Abs and TILs prevalence in pituitary adenomas and their influence on clinical outcome.
  • PATIENTS AND SETTING: Two hundred ninety-one pituitary adenoma cases (110 non-secreting, 30 ACTH-69 GH-71 prolactin- and 13 TSH-secreting adenoma; 177 operated and 114 untreated), 409 healthy controls, and 14 autoimmune hypophysitis were enrolled in a tertiary referral center.
  • The presence of TILs was evaluated using CD45 staining in a subset of adenomas surgically treated (n = 72).
  • MAIN OUTCOME MEASURE: Clinical response of pituitary adenoma after surgery was evaluated.
  • RESULTS: Pit Abs prevalence was higher in adenomas (5.1%) than healthy subjects (0.7%, P < 0.0001) and lower than in autoimmune hypophysitis patients (57%, P < 0.0001).
  • Similarly, TILs prevalence was higher in adenomas than normal pituitary (P = 0.01) and lower than in autoimmune hypophysitis (P < 0.0001).
  • A poor clinical outcome was more common in adenoma patients with TILs (11 of 18, 61%) than in those without (17 of 54, 31%, P = 0.026).
  • Multivariate regression analysis identified the presence of TILs as independent prognostic factor for persistence/recurrence of pituitary adenoma.
  • CONCLUSIONS: TILs and Pit Abs are present in a significant number of pituitary adenoma patients.
  • Cell-mediated immunity appears to be predictive of a less favorable clinical outcome.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Horm Res. 2001;55(6):288-92 [11805433.001]
  • [Cites] Pituitary. 2011 Dec;14(4):388-94 [19466616.001]
  • [Cites] Eur J Cancer. 2002 Oct;38(15):2014-9 [12376206.001]
  • [Cites] J Endocrinol. 2002 Nov;175(2):417-23 [12429039.001]
  • [Cites] Eur J Endocrinol. 2002 Dec;147(6):767-75 [12457452.001]
  • [Cites] N Engl J Med. 2003 Jan 16;348(3):203-13 [12529460.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Feb;88(2):650-4 [12574195.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7 [12826605.001]
  • [Cites] Endocr J. 2003 Dec;50(6):697-702 [14709840.001]
  • [Cites] Endocrine. 2003 Dec;22(3):335-40 [14709807.001]
  • [Cites] Lancet. 1987 Jun 20;1(8547):1394-8 [2884495.001]
  • [Cites] J Clin Endocrinol Metab. 1988 Oct;67(4):633-8 [3417843.001]
  • [Cites] J Endocrinol Invest. 1991 Sep;14(8):691-6 [1774454.001]
  • [Cites] Clin Endocrinol (Oxf). 1993 May;38(5):495-500 [8080469.001]
  • [Cites] Acta Neurochir (Wien). 1994;126(1):38-43 [8154320.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Dec;80(12):3421-4 [8530576.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):609-18 [9467582.001]
  • [Cites] J Lab Clin Med. 1998 Jul;132(1):25-31 [9665368.001]
  • [Cites] Endocr J. 1998 Jun;45(3):357-61 [9790270.001]
  • [Cites] Endocr Rev. 2005 Aug;26(5):599-614 [15634713.001]
  • [Cites] J Neurosurg. 2006 Aug;105(2):309-14 [17219839.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Feb;92(2):604-7 [17090639.001]
  • [Cites] Neurol Med Chir (Tokyo). 2007 Mar;47(3):136-9 [17384498.001]
  • [Cites] J Thorac Oncol. 2006 Jul;1(6):513-9 [17409910.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jun;92(6):2176-81 [17341554.001]
  • [Cites] Ann N Y Acad Sci. 2007 Jun;1107:129-35 [17804540.001]
  • [Cites] J Endocrinol Invest. 2007 Sep;30(8):677-83 [17923800.001]
  • [Cites] Neurosurg Rev. 2008 Apr;31(2):157-63 [18253771.001]
  • [Cites] Endocr J. 2000 Aug;47(4):407-16 [11075721.001]
  • [Cites] Immunol Rev. 2008 Apr;222:101-16 [18363996.001]
  • [Cites] Immunol Rev. 2008 Apr;222:328-40 [18364012.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 2008 May-Jun;56(3):181-91 [18512029.001]
  • [Cites] Clin Endocrinol (Oxf). 2008 Aug;69(2):269-78 [18194487.001]
  • [Cites] Endocr J. 2008 Aug;55(4):729-35 [18497455.001]
  • [Cites] Am J Surg Pathol. 2008 Nov;32(11):1661-6 [18753941.001]
  • [Cites] Histochem Cell Biol. 2008 Dec;130(6):1079-90 [18953558.001]
  • [Cites] Cancer Immun. 2008;8:16 [19053167.001]
  • [Cites] Cancer Lett. 2009 Jun 18;278(2):123-9 [18930343.001]
  • [Cites] No Shinkei Geka. 2002 Jan;30(1):95-9 [11806114.001]
  • (PMID = 19875479.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R21 DK080351; United States / NIDDK NIH HHS / DK / DK080351
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers
  • [Other-IDs] NLM/ PMC2805498
  •  go-up   go-down


50. Nosho K, Yamamoto H, Takamaru H, Hamamoto Y, Goto A, Yoshida Y, Arimura Y, Endo T, Hirata K, Imai K: A case of colorectal carcinoma in adenoma analyzed by a cDNA array. Int J Colorectal Dis; 2005 May;20(3):287-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of colorectal carcinoma in adenoma analyzed by a cDNA array.
  • Colonoscopy showed a Is-type tumor of 45 mm in diameter in the cecum and three Is-type tumors in the ascending colon.
  • Microscopically, the large tumor consisted of a well-differentiated adenocarcinoma with a tubulovillous adenoma (TVA) component (carcinoma in adenoma).
  • All of the four tumor tissues were classified as microsatellite stable (MSS) according to the National Cancer Institute guideline for analysis of microsatellite instability (MSI).
  • K-ras mutation was detected in both CA and TVA lesions of the carcinoma in adenoma.
  • To clarify relevant alterations of gene expression associated with adenoma-carcinoma progression, the gene expression profiles of these tumor tissues were analyzed by a cDNA array.
  • The results were further substantiated by comparison of the gene expression profiles of CA and TVA lesions of the carcinoma in adenoma.
  • CONCLUSION: The results suggest that overexpression of IGF-II played an important role in the progression of adenoma to carcinoma in this patient.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma, Villous / genetics. Colorectal Neoplasms / genetics. DNA, Complementary / analysis. Neoplasms, Multiple Primary
  • [MeSH-minor] Aged. Biomarkers, Tumor / genetics. Colonoscopy. Diagnosis, Differential. Female. Follow-Up Studies. Gene Expression Regulation, Neoplastic / physiology. Genes, ras / genetics. Humans. Immunohistochemistry. Insulin-Like Growth Factor II / genetics. Mutation. Pedigree. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1990 Sep 15;46(3):405-10 [1975564.001]
  • [Cites] Endoscopy. 2001 Apr;33(4):367-73 [11315901.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Gut. 1999 May;44(5):704-8 [10205209.001]
  • [Cites] Br J Cancer. 1997;76(1):60-6 [9218734.001]
  • [Cites] Oncogene. 2002 Jun 13;21(26):4120-8 [12037668.001]
  • [Cites] Oncology. 2000 Sep;59(3):210-6 [11053988.001]
  • [Cites] Cancer Res. 1986 Dec;46(12 Pt 1):6169-73 [3779638.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] J Gastroenterol. 2002 Nov;37 Suppl 14:83-6 [12572872.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3124-30 [11306497.001]
  • (PMID = 15490195.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Complementary; 0 / RNA, Messenger; 67763-97-7 / Insulin-Like Growth Factor II
  •  go-up   go-down


51. Iwai Y, Yamanaka K, Yoshioka K, Yoshimura M, Honda Y, Matsusaka Y, Komiyama M, Yasui T: [The usefulness of adjuvant therapy using gamma knife radiosurgery for the recurrent or residual nonfunctioning pituitary adenomas]. No Shinkei Geka; 2005 Aug;33(8):777-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The usefulness of adjuvant therapy using gamma knife radiosurgery for the recurrent or residual nonfunctioning pituitary adenomas].
  • We evaluated the treatment results of nonfunctioning pituitary adenomas in the era of radiosurgery.
  • Between January 1994 and December 2003, we operated on 44 patients with nonfunctioning pituitary adenomas.
  • Gamma knife radiosurgery was performed for residual tumor in 26 patients and for recurrence in 2 patients.
  • The mean tumor diameter at the gamma knife radiosurgery was 18.2 mm (7.9 to 26.3 mm).
  • The treatment dose was a mean of 12.3 Gy (8 to 16 Gy) to the tumor margin.
  • Tumor growth control was able to be achieved in 26 patients (93%).
  • Surgical resection using transsphenoidal surgery and subsequent gamma knife radiosurgery for residual and recurrent tumor proved to have a highly effective tumor growth control rate, and maintained the quality of life in patients with nonfunctioning pituitary adenomas.
  • [MeSH-major] Adenoma / surgery. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery. Pituitary Neoplasms / surgery. Radiosurgery

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16095207.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


52. Zermani R, Chelbi E, Farah F, Rameh S, Kourda N, Ferchichi L, Sayari S, Zaouche A, Ben Jilani S: [Serrated adenoma of the appendix associated with colonic adenocarcinoma]. Tunis Med; 2009 Jan;87(1):97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Serrated adenoma of the appendix associated with colonic adenocarcinoma].
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Appendiceal Neoplasms / pathology. Colonic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19522437.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Tunisia
  •  go-up   go-down


53. Vinikoor LC, Robertson DJ, Baron JA, Silverman WB, Sandler RS: Cholecystectomy and the risk of recurrent colorectal adenomas. Cancer Epidemiol Biomarkers Prev; 2007 Jul;16(7):1523-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cholecystectomy and the risk of recurrent colorectal adenomas.
  • Prior studies have shown an increased risk of colorectal cancer following cholecystectomy, but few studies have explored the association between cholecystectomy and the risk of colorectal adenomas.
  • We used data from three large randomized adenoma chemoprevention trials to explore the association between cholecystectomy and the occurrence of adenomas.
  • After adjusting for confounding factors, we found no increased risk for adenomas among individuals who had undergone cholecystectomy [risk ratio (RR), 1.02; 95% confidence interval (95% CI), 0.88-1.18].
  • There was a slight increase in the risk of advanced recurrent adenomas (RR, 1.28; 95% CI, 0.94-1.76) and multiple advanced recurrent adenomas (RR, 1.34; 95% CI, 0.97-1.85) but the 95% CIs included the null in both cases.
  • We conclude that the increased risk for colorectal cancer following cholecystectomy seems to be due to a biological process occurring after the adenoma has developed.
  • [MeSH-major] Adenoma / etiology. Cholecystectomy / adverse effects. Colorectal Neoplasms / etiology. Neoplasm Recurrence, Local / etiology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17627020.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK34987; United States / NIDDK NIH HHS / DK / R01 DK44684; United States / NIDDK NIH HHS / DK / T32 DK07634
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


54. Patel N, Talwar A, Donahue L, John V, Margouleff D: Hyperparathyroidism accompanying multiple myeloma. Clin Nucl Med; 2005 Aug;30(8):540-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hypercalcemia is a manifestation of a variety of both benign and malignant diseases.
  • These conditions are not mutually exclusive, and we present a case report of a patient first diagnosed with the classic findings of multiple myeloma who, after appropriate therapy, demonstrated persistent hypercalcemia and was found on further testing to have an elevated parathormone level (PTH) and scintigraphic evidence of a benign parathyroid adenoma.
  • Hypercalcemia responded to excision of the parathyroid adenoma.
  • [MeSH-major] Adenoma / complications. Hyperparathyroidism / etiology. Multiple Myeloma / drug therapy. Parathyroid Neoplasms / complications

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16024948.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  • [Number-of-references] 18
  •  go-up   go-down


55. Kaminski MF, Regula J, Kraszewska E, Polkowski M, Wojciechowska U, Didkowska J, Zwierko M, Rupinski M, Nowacki MP, Butruk E: Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med; 2010 May 13;362(19):1795-803
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Although rates of detection of adenomatous lesions (tumors or polyps) and cecal intubation are recommended for use as quality indicators for screening colonoscopy, these measurements have not been validated, and their importance remains uncertain.
  • The endoscopist's rate of detection of adenomas was significantly associated with the risk of interval colorectal cancer (P=0.008), whereas the rate of cecal intubation was not significantly associated with this risk (P=0.50).
  • The hazard ratios for adenoma detection rates of less than 11.0%, 11.0 to 14.9%, and 15.0 to 19.9%, as compared with a rate of 20.0% or higher, were 10.94 (95% confidence interval [CI], 1.37 to 87.01), 10.75 (95% CI, 1.36 to 85.06), and 12.50 (95% CI, 1.51 to 103.43), respectively (P=0.02 for all comparisons).
  • CONCLUSIONS: The adenoma detection rate is an independent predictor of the risk of interval colorectal cancer after screening colonoscopy.
  • [MeSH-major] Adenoma / diagnosis. Clinical Competence. Colonic Polyps / diagnosis. Colonoscopy / standards. Colorectal Neoplasms / diagnosis. Quality Indicators, Health Care


56. Steinmetz J, Spyckerelle Y, Guéguen R, Dupré C: Colorectal cancer screening in Health Examination Centers. Gastroenterol Clin Biol; 2006 Jun-Jul;30(6-7):832-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A colonic exploration was performed in 69% of high-risk subjects and enabled detection of cancer in 85 and adenomas in 1683.
  • A colonic exploration was performed in 88% of subjects with a positive fecal occult blood test and enabled detection of 674 cancers (positive predictive value of fecal occult blood test (PPV)=4.7%) including 174 Dukes A, and 2618 adenomas (PPV=18%) including 776 adenomas measuring more than 10 mm (PPV=5.4%).
  • [MeSH-major] Adenoma / diagnosis. Colorectal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16885866.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] France
  •  go-up   go-down


57. Bampton PA, Sandford JJ, Cole SR, Smith A, Morcom J, Cadd B, Young GP: Interval faecal occult blood testing in a colonoscopy based screening programme detects additional pathology. Gut; 2005 Jun;54(6):803-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: The main aim of this study was to determine whether a one-off interval faecal occult blood test (FOBT) facilitates the detection of significant neoplasia within a colonoscopic based surveillance programme.
  • Secondary aims were to determine if invitees were interested in participating in interval screening, and to determine whether interval lesions were missed or whether they developed rapidly since the previous colonoscopy PATIENTS: Patients enrolled in a colonoscopic based screening programme due to a personal history of colorectal neoplasia or a significant family history.
  • A positive result was followed by colonoscopy; significant neoplasia was defined as colorectal cancer, adenomas either > or =10 mm or with a villous component, high grade dysplasia, or multiplicity (>/=3 adenomas).
  • These consisted of six colorectal cancers and eight significant adenomas.
  • CONCLUSIONS: A one off immunochemical faecal occult blood test within a colonoscopy based surveillance programme had a participation rate of nearly 50% and appeared to detect additional pathology, especially in patients with a past history of colonic neoplasia.

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med J Aust. 2002 Feb 18;176(4):155-7 [11913914.001]
  • [Cites] J Med Screen. 2002;9(4):147-52 [12518003.001]
  • [Cites] Colorectal Dis. 2003 Jan;5(1):45-8 [12780926.001]
  • [Cites] J Med Screen. 2003;10(3):123-8 [14561263.001]
  • [Cites] Gastroenterology. 1987 Nov;93(5):1009-13 [3653628.001]
  • [Cites] Am J Gastroenterol. 1999 Jan;94(1):194-9 [9934755.001]
  • [Cites] N Engl J Med. 1993 May 13;328(19):1365-71 [8474513.001]
  • [Cites] Aust N Z J Surg. 1994 Jul;64(7):464-9 [8010915.001]
  • [Cites] N Engl J Med. 1996 Jan 18;334(3):155-9 [8531970.001]
  • [Cites] Gastroenterology. 1997 Feb;112(2):594-642 [9024315.001]
  • [Cites] N Engl J Med. 1993 Apr 1;328(13):901-6 [8446136.001]
  • (PMID = 15888788.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1774549
  •  go-up   go-down


58. Cherebillo VIu, Gofman VR, Polezhaev AV: [Transsphenoidal surgery for large and giant pituitary adenomas by intraoperative video endomonitoring]. Zh Vopr Neirokhir Im N N Burdenko; 2005 Jan-Mar;(1):12-5; discussion 15-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transsphenoidal surgery for large and giant pituitary adenomas by intraoperative video endomonitoring].
  • The paper analyzes the outcomes of surgical treatment of patients with pituitary adenomas on the basis of 614 performed transsphenoidal surgical appliances, of which there were 209 large and giant pituitary adenomas.
  • The use of intraoperative video endomonitoring during these interventions could substantially reduced the number of complications, enhance the radicalism and selectivity of a surgical appliance.
  • By using such advantages as endoscopy as powerful lighting, an endomicroscopic phenomenon, and a lateral view, at surgery we could precisely determine the borders of an adenoma, the site and sizes of non-removed tumors fragments.
  • The lateral view of an endoscope permits removal of a tumor via the optimal access, prevention of traumatization of cerebral structures and the contents of cavernous sinuses.
  • Thus, the accumulated experience allows the authors to recommend using intraoperative video endomonitoring during transsphenoidal surgery for pituitary adenomas.
  • [MeSH-major] Adenoma / surgery. Neuroendoscopy. Pituitary Neoplasms / surgery. Sphenoid Sinus / surgery. Video-Assisted Surgery

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15912863.001).
  • [ISSN] 0042-8817
  • [Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko
  • [ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


59. Harris DL, Washington MK, Hood DB, Roberts LJ 2nd, Ramesh A: Dietary fat-influenced development of colon neoplasia in Apc Min mice exposed to benzo(a)pyrene. Toxicol Pathol; 2009 Dec;37(7):938-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary fat-influenced development of colon neoplasia in Apc Min mice exposed to benzo(a)pyrene.
  • An increased prevalence of adenomas in colons of mice that ingested B(a)P through saturated dietary fat compared to unsaturated fat and controls (p < .05) was noticed.
  • Interestingly, we also observed adenomas with high-grade dysplasia in the B(a)P + saturated fat group, and these incidences were frequent at the 100 microg/kg B(a)P dose.
  • On the other hand, the B(a)P-alone and unsaturated-fat groups did not show significant differences in the numbers of adenomas and invasive tumors in the both jejunum and the colon.

  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Benzo(a)pyrene .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prog Lipid Res. 1999 May;38(3):261-71 [10664796.001]
  • [Cites] J Lipid Res. 1985 Apr;26(4):428-34 [4009061.001]
  • [Cites] J Agric Food Chem. 2001 May;49(5):2493-6 [11368625.001]
  • [Cites] Dig Dis Sci. 2001 Jul;46(7):1367-80 [11478486.001]
  • [Cites] Carcinogenesis. 2002 Jul;23(7):1131-7 [12117770.001]
  • [Cites] Chemosphere. 2002 Sep;48(8):843-8 [12222778.001]
  • [Cites] Carcinogenesis. 2002 Nov;23(11):1839-49 [12419832.001]
  • [Cites] J Biochem Mol Biol. 2003 Jan 31;36(1):35-42 [12542973.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):762-77 [12612914.001]
  • [Cites] Nutr Rev. 2003 Jul;61(7):255-8 [12918879.001]
  • [Cites] Reprod Nutr Dev. 2003 Mar-Apr;43(2):145-54 [12956314.001]
  • [Cites] Exp Toxicol Pathol. 2003 Sep;55(2-3):91-106 [14620530.001]
  • [Cites] Free Radic Res. 2003 Sep;37(9):947-56 [14670002.001]
  • [Cites] Int J Cancer. 1990 Oct 15;46(4):640-7 [2210884.001]
  • [Cites] Mutat Res. 1991 Mar-Apr;259(3-4):251-61 [2017211.001]
  • [Cites] Cell. 1991 Aug 9;66(3):601-13 [1678319.001]
  • [Cites] Toxicol Ind Health. 1991 May;7(3):141-57 [1949056.001]
  • [Cites] J Cell Biol. 1992 Mar;116(6):1517-26 [1541640.001]
  • [Cites] Science. 1992 May 1;256(5057):668-70 [1350108.001]
  • [Cites] Lipids. 1992 Oct;27(10):807-13 [1435100.001]
  • [Cites] Environ Health Perspect. 1993 Oct;101 Suppl 3:37-42 [8143643.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Carcinogenesis. 1997 Apr;18(4):721-30 [9111206.001]
  • [Cites] Carcinogenesis. 1999 Jun;20(6):1097-101 [10357794.001]
  • [Cites] Semin Cancer Biol. 1999 Aug;9(4):245-54 [10448112.001]
  • [Cites] J Cell Biochem. 2004 Dec 15;93(6):1242-54 [15486983.001]
  • [Cites] Recent Results Cancer Res. 2005;166:177-211 [15648191.001]
  • [Cites] Science. 2005 Mar 25;307(5717):1904-9 [15790842.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1626-32 [16030093.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):2030-4 [16103456.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):8034-41 [16140978.001]
  • [Cites] Cancer Lett. 2006 Aug 28;240(2):268-78 [16288829.001]
  • [Cites] Carcinogenesis. 2006 Oct;27(10):2038-46 [16675473.001]
  • [Cites] Curr Opin Gastroenterol. 2007 Jan;23(1):48-54 [17133085.001]
  • [Cites] J Nutr Biochem. 2007 Apr;18(4):236-49 [16781860.001]
  • [Cites] Genes Dev. 2007 Oct 15;21(20):2525-38 [17938238.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):9937-44 [17942926.001]
  • [Cites] Int J Environ Res Public Health. 2008 Mar;5(1):41-8 [18441404.001]
  • [Cites] Pathol Res Pract. 2008;204(7):479-90 [18538487.001]
  • [Cites] Cancer Res. 2008 Sep 15;68(18):7394-402 [18794127.001]
  • [Cites] Planta Med. 2008 Oct;74(13):1602-7 [18604780.001]
  • [Cites] Carcinogenesis. 2009 Feb;30(2):183-96 [19037092.001]
  • [Cites] Oncogene. 1999 Sep 20;18(38):5325-33 [10498885.001]
  • [Cites] J Food Prot. 2003 Dec;66(12):2325-31 [14672232.001]
  • [Cites] J Nutr. 2004 Apr;134(4):776-84 [15051825.001]
  • [Cites] Environ Mol Mutagen. 2004;44(1):44-55 [15199546.001]
  • [Cites] Int J Toxicol. 2004;23(5):301-33 [15513831.001]
  • [Cites] J Lipid Res. 1984 Dec 1;25(12):1337-42 [6530591.001]
  • [Cites] Curr Opin Oncol. 2001 Jan;13(1):63-9 [11148689.001]
  • (PMID = 19841130.001).
  • [ISSN] 1533-1601
  • [Journal-full-title] Toxicologic pathology
  • [ISO-abbreviation] Toxicol Pathol
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / F31 ES017391-01; United States / NCI NIH HHS / CA / R03 CA130112; United States / NIEHS NIH HHS / ES / F31 ES017391; United States / NIEHS NIH HHS / ES / 1S11ES014156-01A1; United States / NHLBI NIH HHS / HL / T32 HL007735-12; United States / NIEHS NIH HHS / ES / S11 ES014156; United States / NCI NIH HHS / CA / R03 CA130112-01; United States / NCI NIH HHS / CA / R01 CA142845; United States / NCI NIH HHS / CA / 1R03CA130112-01; United States / NHLBI NIH HHS / HL / 5T32HL007735-12; United States / NHLBI NIH HHS / HL / T32 HL007735; United States / NIEHS NIH HHS / ES / S11 ES014156-01A1; United States / NIEHS NIH HHS / ES / 1F31ES017391-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Dietary Fats; 3417WMA06D / Benzo(a)pyrene
  • [Other-IDs] NLM/ NIHMS248414; NLM/ PMC2982189
  •  go-up   go-down


60. Onofri C, Losa M, Uhl E, Stalla GK, Renner U: Immunohistochemical analysis of VEGF-C/VEGFR-3 system and lymphatic vessel extent in normal and adenomatous human pituitary tissues. Exp Clin Endocrinol Diabetes; 2008 Mar;116(3):152-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analysis of VEGF-C/VEGFR-3 system and lymphatic vessel extent in normal and adenomatous human pituitary tissues.
  • We assessed the expression of VEGF-C and VEGFR-3, together with blood and lymphatic vessel extents and proliferation index (PI) values, by immunohistochemistry (IHC) in 6 normal human pituitary glands and 53 pituitary adenomas of different tumour grade, on consecutive tissue sections.
  • VEGF-C was detected in around 10% of the endocrine cells in normal pituitary tissue, while this gland was devoid of lymphatic vascularization and showed very few vessels positive for VEGFR-3.
  • Concerning tumour tissue, most of the adenomas showing VEGF-C immunoreactivity (21/47) were positive in 60% of the tumour cells and the ones positive for VEGFR-3 showed a number of immunostained vessels higher than those observed in the normal pituitary.
  • In conclusion, the VEGF-C/VEGFR-3 system might be involved in controlling tumour angiogenesis in the pituitary adenomas lacking lymphatic vessels, but may also play a role in starting the process of tumour lymphangiogenesis.
  • [MeSH-major] Adenoma / metabolism. Lymphatic Vessels / metabolism. Pituitary Neoplasms / metabolism. Vascular Endothelial Growth Factor C / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18205092.001).
  • [ISSN] 0947-7349
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor C; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


61. Mahe E, El-Shinnawy I: A "tumour trifecta:" myelolipomata arising within an adrenocortical adenoma ipsilateral to a synchronous clear cell renal cell carcinoma. Malays J Pathol; 2010 Dec;32(2):123-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A "tumour trifecta:" myelolipomata arising within an adrenocortical adenoma ipsilateral to a synchronous clear cell renal cell carcinoma.
  • We present an intriguing case of adrenal myelolipomata occurring within an adrenocortical adenoma in concert with an ipsilateral clear cell renal cell carcinoma.
  • The adrenal mass was a cortical adenoma with solid and nested patterns, with discrete zones consisting of erythroid, myeloid and megakaryocytic cells intermixed with mature adipocytes.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Adenoma / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Myelolipoma / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Middle Aged


62. Anaforoğlu I, Siviloğlu C, Livaoğlu A, Algün E: Granulomatous infiltration of a parathyroid adenoma presenting as primary hyperparathyroidism in a woman: a case report. J Med Case Rep; 2010;4:400
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulomatous infiltration of a parathyroid adenoma presenting as primary hyperparathyroidism in a woman: a case report.
  • Although most patients with granulomatous disease-related hypercalcemia are asymptomatic, symptoms and signs of chronic hypercalcemia can occur.
  • There are many reports about co-presentation of a parathyroid adenoma and a granulomatous disorder in the literature.
  • However, granulomatous inflammation within a parathyroid adenoma is very rare.
  • She underwent excision of an enlarged right inferior parathyroid gland.
  • Histopathological analysis revealed features of a parathyroid adenoma with foci of epithelioid non-caseating granulomas.
  • She is still normocalcemic at the ninth month after surgery and is being followed for the possible manifestation of an occult disease.
  • CONCLUSION: Granulomatous infiltration of a parathyroid adenoma is a rare condition.
  • Pathological examination of the excised adenoma is the only way to diagnose the underlying occult granulomatous disorder.
  • Clinicians should also consider persistent hypercalcemia to be a possible indicator of concomitant parathyroid adenoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Pathol. 2001 Fall;12(3):355-9 [11740057.001]
  • [Cites] Endocr Pathol. 2005 Summer;16(2):157-60 [16199902.001]
  • [Cites] Arch Intern Med. 1980 Nov;140(11):1547-8 [7436654.001]
  • [Cites] Arch Otorhinolaryngol. 1987;243(6):392-4 [3566623.001]
  • [Cites] J Nephrol. 2008 May-Jun;21(3):438-41 [18587734.001]
  • (PMID = 21143903.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3019160
  •  go-up   go-down


63. Makino K, Kojima R, Nakamura H, Morioka M, Iyama K, Shigematsu K, Kuratsu J: Ectopic adrenal cortical adenoma in the spinal region: case report and review of the literature. Brain Tumor Pathol; 2010 Oct;27(2):121-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopic adrenal cortical adenoma in the spinal region: case report and review of the literature.
  • Immunohistochemically, the tumor cells were strongly positive for inhibin-alpha, positive for synaptophysin and vimentin, and negative for GFAP, EMA, S-100, NSA, and chromogranin A.
  • This case confirms the occurrence of adrenocortical adenoma in the CNS.
  • We suggest that this tumor should be considered in the differential diagnosis of CNS tumors.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Adenoma / pathology. Spinal Cord Neoplasms / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21046315.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Steroidogenic Factor 1; 0 / inhibin-alpha subunit; 57285-09-3 / Inhibins
  •  go-up   go-down


64. Cavallo LM, Prevedello D, Esposito F, Laws ER Jr, Dusick JR, Messina A, Jane JA Jr, Kelly DF, Cappabianca P: The role of the endoscope in the transsphenoidal management of cystic lesions of the sellar region. Neurosurg Rev; 2008 Jan;31(1):55-64; discussion 64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystic mass lesions within the sella turcica are common, and they include cystic pituitary adenomas, craniopharyngiomas, Rathke's cleft cysts, arachnoid cysts, and other entities.
  • The series consisted of 26 pituitary macroadenomas, 20 Rathke's cleft cysts, 18 craniopharyngiomas, 10 arachnoid cysts, one craniopharyngioma associated with an adrenocorticotropic hormone-secreting adenoma, and one chordoid glioma.
  • Endoscopic exploration of the sellar cavity during transsphenoidal surgery offers both general and specific advantages in the treatment of a variety of different cystic sellar lesions.
  • Its routine use during transsphenoidal surgery for such lesions is recommended to achieve maximal and safe tumor removal.
  • [MeSH-minor] Adenoma / surgery. Adult. Aged. Arachnoid Cysts / surgery. Central Nervous System Cysts / surgery. Craniopharyngioma / surgery. Female. Humans. Male. Middle Aged. Neurosurgical Procedures / instrumentation. Neurosurgical Procedures / methods. Pituitary Neoplasms / surgery. Sphenoid Sinus

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1991 Jun;35(6):446-54 [2053058.001]
  • [Cites] Front Horm Res. 2006;34:105-26 [16474218.001]
  • [Cites] Neurosurgery. 2005;56(1):124-8; discussion 129 [15617594.001]
  • [Cites] Neurosurgery. 1998 Jan;42(1):7-16; discussion 16-7 [9442498.001]
  • [Cites] Diagn Cytopathol. 1999 Mar;20(3):137-47 [10086237.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(2):165-9 [10189498.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Nov;84(11):3972-82 [10566636.001]
  • [Cites] Neurosurgery. 2004 Oct;55(4):933-40; discussion 940-1 [15458602.001]
  • [Cites] Childs Nerv Syst. 2005 Aug;21(8-9):696-700 [16041618.001]
  • [Cites] Surg Neurol. 1981 Apr;15(4):274-82 [7245014.001]
  • [Cites] Minim Invasive Neurosurg. 2002 Mar;45(1):47-51 [11932826.001]
  • [Cites] J Neurosurg. 1984 Jan;60(1):8-13 [6689730.001]
  • [Cites] Skull Base. 2003 Feb;13(1):55-58 [15912160.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(4):389-97; discussion 397-8 [10352749.001]
  • [Cites] Childs Nerv Syst. 2004 Nov;20(11-12):863-7 [15185112.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):237-50 [9950494.001]
  • [Cites] J Neurosurg. 1970 Jul;33(1):48-53 [5427027.001]
  • [Cites] J Neurosurg. 1980 May;52(5):661-6 [7373393.001]
  • [Cites] J Endocrinol Invest. 2004 Nov;27(10):943-8 [15762042.001]
  • [Cites] Pediatr Neurosurg. 1994;21 Suppl 1:57-63 [7841079.001]
  • [Cites] J Neurosurg. 2002 Jul;97(1):3-11 [12134929.001]
  • [Cites] Laryngoscope. 1996 Jul;106(7):914-8 [8667994.001]
  • [Cites] J Neurosurg. 2003 Feb;98(2):350-8 [12593622.001]
  • [Cites] Neurosurgery. 2001 Jul;49(1):94-100; discussion 100-1 [11440465.001]
  • [Cites] AJNR Am J Neuroradiol. 1994 May;15(5):821-7 [8059648.001]
  • [Cites] J Neurosurg. 1977 Sep;47(3):451-8 [894347.001]
  • (PMID = 17922153.001).
  • [ISSN] 0344-5607
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


65. Sathyapalan T, Lowry M, Turnbull LW, Rowland-Hill C, Atkin SL: Mechanism of action of octreotide in acromegalic tumours in vivo using dynamic contrast-enhanced magnetic resonance imaging. Pituitary; 2007;10(3):233-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Amplitude of contrast intake (9.87 +/- 3.52 vs. 4.97 +/- 1.96 P < or = 0.05) and exchange rate (6.27 +/- 1.57 vs. 1.63 +/- 0.76 P value < or = 0.01) were significantly higher at baseline in adenoma compared to normal pituitary tissue but was comparable to normal pituitary tissue after treatment.
  • There was a significant decrease in amplitude of contrast intake and exchange rate which relates to functional vascularity of adenoma at 24 weeks compared to baseline (P-values 0.026 and 0.002 respectively) but there were no significant changes in the normal pituitary tissue.
  • CONCLUSION: DCE-MRI in acromegalic tumours treated with octreotide showed a significant reduction in functional vascularity after octreotide therapy compared to baseline in pituitary adenomas.
  • [MeSH-major] Acromegaly / drug therapy. Adenoma / drug therapy. Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Growth Hormone-Secreting Pituitary Adenoma / drug therapy. Octreotide / therapeutic use
  • [MeSH-minor] Adult. Aged. Contrast Media. Drug Resistance, Neoplasm. Female. Gadolinium DTPA. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Regional Blood Flow / drug effects. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1856-63 [15613435.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Oct;57(4):425-41 [12354124.001]
  • [Cites] Semin Oncol. 1994 Oct;21(5 Suppl 13):61-4 [7992085.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jul;88(7):3105-12 [12843150.001]
  • [Cites] J Comput Assist Tomogr. 1991 Jul-Aug;15(4):621-8 [2061479.001]
  • [Cites] Technol Cancer Res Treat. 2006 Apr;5(2):127-34 [16551132.001]
  • [Cites] Eur J Endocrinol. 2001 Dec;145(6):717-26 [11720896.001]
  • [Cites] Magn Reson Med. 1991 Feb;17(2):357-67 [2062210.001]
  • [Cites] Magn Reson Med. 1992 Mar;24(1):174-6 [1556924.001]
  • [Cites] J Neurosurg. 2002 Sep;97(3):525-30 [12296634.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):1287-9 [10720077.001]
  • [Cites] Magn Reson Imaging. 1996;14(4):373-80 [8782175.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1580-4 [7878022.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1493-8 [15812556.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Nov;86(11):5194-200 [11701676.001]
  • [Cites] J Physiol Paris. 2000 May-Aug;94(3-4):205-10 [11087998.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Aug;90(8):4483-8 [15899958.001]
  • [Cites] Pharmacol Ther. 2004 Apr;102(1):61-85 [15056499.001]
  • [Cites] Int J Clin Pharmacol Ther. 2002 Dec;40(12):573-4 [12503819.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Oct;87(10):4554-63 [12364434.001]
  • [Cites] Int J Clin Pharmacol Ther. 2003 Dec;41(12):600-2 [14692711.001]
  • (PMID = 17541750.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents, Hormonal; 0 / Contrast Media; 51110-01-1 / Somatostatin; K2I13DR72L / Gadolinium DTPA; RWM8CCW8GP / Octreotide
  •  go-up   go-down


66. Lee SE, Park NH, Park IA, Kang SB, Lee HP: Tubulo-villous adenoma of the vagina. Gynecol Oncol; 2005 Feb;96(2):556-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubulo-villous adenoma of the vagina.
  • BACKGROUND: Tubulo-villous adenomas are common in the colon and rectum, but extremely rare in the vagina.
  • As far as we know, only two cases of tubulo-villous adenoma have ever been reported.
  • We report the third case of enteric-type tubulo-villous adenoma of the vagina.
  • CASE: A 61-year-old woman presented a symptom of intermittent vaginal spotting and a tumor located outside the vaginal introitus near the urethra.
  • The tumor was excised and pathologically confirmed as a tubulo-villous adenoma.
  • CONCLUSION: Because some tubulo-villous adenomas in the colon and rectum can progress to the cancer, this case requires long-term follow-up to detect recurrence and malignant transformation.
  • [MeSH-major] Adenoma, Villous / pathology. Vaginal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15661252.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 17
  •  go-up   go-down


67. Alzahrani AS, Farhat R, Al-Arifi A, Al-Kahtani N, Kanaan I, Abouzied M: The diagnostic value of fused positron emission tomography/computed tomography in the localization of adrenocorticotropin-secreting pituitary adenoma in Cushing's disease. Pituitary; 2009;12(4):309-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnostic value of fused positron emission tomography/computed tomography in the localization of adrenocorticotropin-secreting pituitary adenoma in Cushing's disease.
  • Despite the high resolution of magnetic resonance imaging (MRI) of the pituitary gland, up to 40% of cases of Cushing's disease (CD) have normal MRI.
  • Objective of this study is to explore the diagnostic potential of PET-CT for localization of adrenocorticotropin-secreting pituitary adenomas in CD.
  • PET-CT was positive in 7 of the 12 cases of CD (58%) showing a focal area of uptake in the pituitary gland.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / diagnosis. Pituitary ACTH Hypersecretion / pathology. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Pituitary Gland / metabolism. Pituitary Gland / pathology

  • MedlinePlus Health Information. consumer health - CT Scans.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Nucl Med. 2002 Mar;27(3):176-8 [11852303.001]
  • [Cites] J Clin Endocrinol Metab. 2004 May;89(5):2214-21 [15126544.001]
  • [Cites] N Engl J Med. 1991 Sep 26;325(13):897-905 [1652686.001]
  • [Cites] AJR Am J Roentgenol. 1994 Sep;163(3):680-2 [8079867.001]
  • [Cites] Rinsho Hoshasen. 1990 Mar;35(3):407-10 [2161060.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Apr;64(4):371-4 [16584507.001]
  • [Cites] Ann Intern Med. 1994 May 15;120(10):817-20 [8154641.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Feb;78(2):418-22 [8106630.001]
  • [Cites] J Nucl Med. 2001 May;42(5 Suppl):1S-93S [11483694.001]
  • [Cites] Lancet. 2006 May 13;367(9522):1605-17 [16698415.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jun;82(6):1780-5 [9177382.001]
  • [Cites] Neurosurgery. 1991 Jun;28(6):826-33 [2067604.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):440-8 [10022398.001]
  • [Cites] J Clin Endocrinol Metab. 2008 May;93(5):1526-40 [18334580.001]
  • [Cites] Clin Endocrinol (Oxf). 1993 Sep;39(3):307-13 [8222293.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Apr;21(4):690-6 [10782779.001]
  • [Cites] Radiology. 1990 Oct;177(1):39-44 [2399336.001]
  • (PMID = 19387839.001).
  • [ISSN] 1573-7403
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Jeong CW, Park YH, Shin CS, Kim HH: Synchronous bilateral laparoendoscopic single-site adrenalectomy. J Endourol; 2010 Aug;24(8):1301-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Abstract We present the first report of simultaneous laparoendoscopic single-site surgery (LESS) for bilateral primary aldosterone-producing adrenal adenomas.
  • A 40-year-old man with hypertension that was resistant to pharmacotherapy was shown to have bilateral aldosterone-producing adrenal adenomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20575688.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Orłowska J: Serrated polyps of the colorectum: histological classification and clinical significance. Pol J Pathol; 2010;61(1):8-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The serrated pathway encompassing hyperplastic aberrant crypt foci, hyperplastic polyps, sessile serrated polyps (adenomas), mixed polyps, and traditional serrated adenomas, with a meticulous review of their up-to-date histological classifications, is presented.
  • [MeSH-major] Adenoma. Colonic Polyps

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20496268.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


70. Shaukat A, Scouras N, Schünemann HJ: Role of supplemental calcium in the recurrence of colorectal adenomas: a metaanalysis of randomized controlled trials. Am J Gastroenterol; 2005 Feb;100(2):390-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of supplemental calcium in the recurrence of colorectal adenomas: a metaanalysis of randomized controlled trials.
  • BACKGROUND: Colorectal adenomas are neoplastic growths that are important targets for chemoprevention.
  • However, the role of calcium supplementation for preventing recurrence of adenomas is controversial.
  • We performed a systematic review and meta-analysis to study the role of calcium supplementation in preventing recurrence of adenomas.
  • RESULTS: We identified three trials including 1,485 subjects with previously removed adenomas who were randomized to calcium versus placebo supplementation.
  • The study endpoint was recurrence of adenomas at the end of 3-4 yr in 1,279 patients who completed the trials.
  • We found that the recurrence of adenomas was significantly lower in subjects randomized to calcium supplementation (RR: 0.80, CI: 0.68, 0.93; p-value = 0.004).
  • CONCLUSIONS: This systematic review and meta-analysis suggest that calcium supplementation prevents recurrent colorectal adenomas.
  • [MeSH-major] Adenoma / prevention & control. Calcium / administration & dosage. Chemoprevention. Colorectal Neoplasms / prevention & control. Dietary Supplements. Neoplasm Recurrence, Local / prevention & control

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Dietary Supplements.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Gastroenterol. 2005 Feb;100(2):395-6 [15667498.001]
  • (PMID = 15667497.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  • [Chemical-registry-number] SY7Q814VUP / Calcium
  •  go-up   go-down


76. Lee SY, Chung H, Devaraj B, Iwaizumi M, Han HS, Hwang DY, Seong MK, Jung BH, Carethers JM: Microsatellite alterations at selected tetranucleotide repeats are associated with morphologies of colorectal neoplasias. Gastroenterology; 2010 Nov;139(5):1519-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We evaluated tumor samples from a cohort of patients that had 24 adenomas and 84 colorectal cancers.
  • EMAST were analyzed after DNA microdissection of matched normal and tumor samples using the polymorphic tetranucleotide microsatellite markers MYCL1, D9S242, D20S85, D8S321, and D20S82; data were compared with clinical and pathology findings.
  • RESULTS: Moderately differentiated adenocarcinomas and poorly differentiated adenocarcinomas had higher frequencies of EMAST (56.9% and 40.0%, respectively) than well-differentiated adenocarcinomas (12.5%) or adenomas (33.3%) (P = .040).
  • CONCLUSIONS: EMAST is acquired during progression of adenoma and well-differentiated carcinomas to moderately and poorly differentiated carcinomas; it correlates with nuclear heterogeneity for hMSH3.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
  • [Cites] BJU Int. 2007 May;99(5):1031-5 [17233803.001]
  • [Cites] J Gastrointest Surg. 2010 Oct;14(10):1521-8 [20844976.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2008 Jul;18(3):581-93, xi [18674705.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2488-91 [10811129.001]
  • [Cites] Int J Cancer. 2001 Jan 15;91(2):200-4 [11146445.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7444-8 [11606378.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 Jul;283(1):C148-54 [12055083.001]
  • [Cites] Oncogene. 2002 Jul 25;21(32):4894-9 [12118368.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1608-14 [12670912.001]
  • [Cites] Oncogene. 2003 Nov 27;22(54):8699-706 [14647464.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1237-40 [8640805.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2509-13 [16380996.001]
  • [Cites] J Mol Med (Berl). 2006 Apr;84(4):329-33 [16416315.001]
  • [Cites] J Mol Med (Berl). 2006 Oct;84(10):833-41 [16924473.001]
  • [Cites] Cancer Res. 2008 Oct 15;68(20):8465-72 [18922920.001]
  • [Cites] Gastroenterology. 2008 Oct;135(4):1079-99 [18773902.001]
  • [Cites] J Exp Clin Cancer Res. 2008;27:88 [19116039.001]
  • [Cites] Oncol Rep. 2010 Feb;23(2):551-61 [20043121.001]
  • [Cites] Fam Cancer. 2008;7(1):41-52 [17636426.001]
  • (PMID = 20708618.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK067287; United States / NCI NIH HHS / CA / CA132384; United States / NCI NIH HHS / CA / U54 CA132384; United States / NIDDK NIH HHS / DK / R24 DK080506; United States / NCI NIH HHS / CA / CA132379; United States / NIDDK NIH HHS / DK / DK067287; United States / NCI NIH HHS / CA / U54 CA132379; United States / NIDDK NIH HHS / DK / DK080506
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / MSH3 protein, human
  • [Other-IDs] NLM/ NIHMS229907; NLM/ PMC2967646
  •  go-up   go-down


77. Hindié E, Ugur O, Fuster D, O'Doherty M, Grassetto G, Ureña P, Kettle A, Gulec SA, Pons F, Rubello D, Parathyroid Task Group of the EANM: 2009 EANM parathyroid guidelines. Eur J Nucl Med Mol Imaging; 2009 Jul;36(7):1201-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary hyperparathyroidism is an endocrine disorder with high prevalence, typically caused by a solitary parathyroid adenoma, less frequently (about 15%) by multiple parathyroid gland disease (MGD) and rarely (1%) by parathyroid carcinoma.
  • Patients with MGD may have a double adenoma or hyperplasia of three or all four parathyroid glands.
  • Scintigraphy should also report on thyroid nodules that may cause confusion with a parathyroid adenoma or require concurrent surgical resection.
  • The guidelines also discuss aspects related to radio-guided surgery of hyperparathyroidism and imaging of chronic kidney disease patients with secondary hyperparathyroidism.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2009 Feb;94(2):335-9 [19193908.001]
  • [Cites] Radiology. 2000 Feb;214(2):393-402 [10671586.001]
  • [Cites] PET Clin. 2007 Jul;2(3):385-93 [27158018.001]
  • [Cites] Arch Pathol Lab Med. 2008 Aug;132(8):1251-62 [18684024.001]
  • [Cites] J Nucl Med. 1998 Jun;39(6):1111-4 [9627355.001]
  • [Cites] Am J Surg. 1996 Dec;172(6):633-6 [8988665.001]
  • [Cites] Head Neck. 2008 Apr;30(4):509-17 [18059012.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Apr;33(4):467-73 [16404597.001]
  • [Cites] Lancet. 1997 Apr 26;349(9060):1233-8 [9130957.001]
  • [Cites] Eur J Nucl Med. 2000 Sep;27(9):1300-4 [11007510.001]
  • [Cites] J Nucl Med. 2007 Jul;48(7):1084-9 [17574983.001]
  • [Cites] Surgery. 2006 Nov;140(5):837-8 [17084734.001]
  • [Cites] Eur J Nucl Med. 1995 Jun;22(6):556-8 [7556303.001]
  • [Cites] Nucl Med Commun. 2003 Feb;24(2):133-40 [12548037.001]
  • [Cites] J Nucl Med. 1998 Oct;39(10):15N, 24N [9776261.001]
  • [Cites] Endocr Pract. 2005 Jan-Feb;11(1):49-54 [16033736.001]
  • [Cites] J Nucl Med. 1992 Oct;33(10 ):1801-7 [1328564.001]
  • [Cites] Surgery. 1997 Mar;121(3):287-94 [9092129.001]
  • [Cites] J Nucl Med. 1992 Mar;33(3):313-8 [1531500.001]
  • [Cites] Panminerva Med. 2002 Jun;44(2):99-105 [12032427.001]
  • [Cites] Nephrol Dial Transplant. 1997 Jan;12 (1):97-100 [9027781.001]
  • [Cites] J Nucl Med. 2003 Sep;44(9):1443-58 [12960191.001]
  • [Cites] Radiology. 2001 Mar;218(3):916-7 [11230677.001]
  • [Cites] J Nucl Med. 1998 Jun;39(6):1100-5 [9627353.001]
  • [Cites] J Nucl Med. 1997 Jun;38(6):831-4 [9189124.001]
  • [Cites] Surgery. 1993 Dec;114(6):1011-8 [8256204.001]
  • [Cites] Nucl Med Commun. 2006 Dec;27(12):977-87 [17088684.001]
  • [Cites] Radiology. 1997 Jul;204(1):221-8 [9205251.001]
  • [Cites] J Nucl Med. 1996 Nov;37(11):1809-15 [8917180.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Jan;81(1):346-52 [8550776.001]
  • [Cites] Semin Ultrasound CT MR. 1995 Aug;16(4):279-95 [7576775.001]
  • [Cites] Lancet. 1999 Jun 26;353(9171):2200-4 [10392985.001]
  • [Cites] Surgery. 1986 Jun;99(6):643-51 [3715716.001]
  • [Cites] Nucl Med Commun. 1989 Nov;10 (11):791-4 [2532313.001]
  • [Cites] J Nucl Med. 2005 Feb;46(2):248-52 [15695783.001]
  • [Cites] Clin Med Res. 2004 Feb;2(1):55-8 [15931335.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Mar;87(3):1024-9 [11889156.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 May;34(5):796-8 [17406866.001]
  • [Cites] Am Surg. 2003 Aug;69(8):720-5 [12953832.001]
  • [Cites] Ann Intern Med. 1991 Apr 1;114(7):593-7 [1900404.001]
  • [Cites] Minerva Endocrinol. 2008 Jun;33(2):95-104 [18268473.001]
  • [Cites] Surgery. 1984 Jan;95(1):14-21 [6691181.001]
  • [Cites] Arch Surg. 2002 Sep;137(9):1055-9 [12215160.001]
  • [Cites] Arch Surg. 2000 Dec;135(12 ):1461-8 [11115353.001]
  • [Cites] World J Surg. 2008 May;32(5):774-81; discussion 782-3 [18335276.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Apr;33(4):453-9 [16435115.001]
  • [Cites] Am J Kidney Dis. 2008 Sep;52(3):519-30 [18514987.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Mar;35(3):637-43 [17960377.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Feb;134(2):316-20 [16455383.001]
  • [Cites] Arch Surg. 2002 Aug;137(8):917-22; discussion 922-3 [12146990.001]
  • [Cites] Nucl Med Commun. 2004 Nov;25(11):1089-93 [15577586.001]
  • [Cites] J Nucl Med. 2004 Jan;45(1):40-8 [14734671.001]
  • [Cites] J Nucl Med. 2008 Dec;49(12):2012-7 [18997051.001]
  • [Cites] Eur J Endocrinol. 1998 Aug;139(2):195-7 [9724076.001]
  • [Cites] Environ Health Perspect. 1997 Dec;105 Suppl 6:1403-9 [9467052.001]
  • [Cites] Surgery. 1997 Dec;122(6):998-1003; discussion 1003-4 [9426412.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):189-2 [12643287.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Aug;57(2):241-9 [12153604.001]
  • [Cites] J Nucl Med. 1996 Nov;37(11):1773-8 [8917173.001]
  • [Cites] Eur J Nucl Med. 1994 Jan;21(1):17-22 [8088281.001]
  • [Cites] Surgery. 1999 Dec;126(6):1023-8; discussion 1028-9 [10598183.001]
  • [Cites] J Nucl Med. 2006 Jul;47(7):1227-34 [16818960.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Jan;80(1):302-7 [7829631.001]
  • [Cites] J Am Coll Surg. 2002 Jul;195(1):19-22 [12113540.001]
  • [Cites] Radiology. 1994 Jul;192(1):280 [8208955.001]
  • [Cites] Clin Nucl Med. 2000 Jul;25(7):527-31 [10885694.001]
  • [Cites] World J Surg. 2006 Jan;30(1):76-83 [16369710.001]
  • [Cites] Br J Surg. 1982 May;69(5):244-7 [7074331.001]
  • [Cites] Arch Surg. 1989 Aug;124(8):911-4; discussion 914-5 [2757503.001]
  • [Cites] J Bone Miner Res. 2002 Nov;17 Suppl 2:N37-43 [12412776.001]
  • [Cites] Arch Surg. 2002 Aug;137(8):967-70 [12147000.001]
  • [Cites] Br J Surg. 1996 Jul;83(7):989-91 [8813796.001]
  • [Cites] Ann Surg Oncol. 2008 Oct;15(10):2653-60 [18677536.001]
  • [Cites] J Nucl Med. 2003 Jun;44(6):904-8 [12791817.001]
  • [Cites] Eur J Nucl Med. 2001 Sep;28(9):1409-20 [11585302.001]
  • [Cites] Radiology. 1998 Apr;207 (1):207-13 [9580138.001]
  • [Cites] Adv Anat Pathol. 2005 Mar;12(2):53-61 [15731573.001]
  • [Cites] J Nucl Med. 1991 Aug;32(8):1627-39 [1869992.001]
  • [Cites] Nucl Med Commun. 1995 Jul;16(7):522-33 [7478389.001]
  • [Cites] Eur J Endocrinol. 2003 Jul;149(1):7-15 [12824860.001]
  • [Cites] J Nucl Med. 1983 May;24(5):438-41 [6842292.001]
  • [Cites] Radiology. 1996 Oct;201(1):85-91 [8816526.001]
  • [Cites] Minerva Endocrinol. 2001 Mar;26(1):3-12 [11323562.001]
  • [Cites] J Nucl Med Technol. 2007 Sep;35(3):135-9 [17702904.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Nov;83(11):3867-71 [9814460.001]
  • [Cites] Eur J Nucl Med. 1996 Jun;23 (6):693-6 [8662105.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2007 Dec;133(12 ):1235-9 [18086965.001]
  • (PMID = 19471928.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 971Z4W1S09 / Technetium Tc 99m Sestamibi; A0730CX801 / Sodium Pertechnetate Tc 99m
  •  go-up   go-down


78. Lin MX, Wen ZF, Feng ZY, He D: [Expression and significance of Bmi-1 and Ki67 in colorectal carcinoma tissues]. Ai Zheng; 2008 Dec;27(12):1321-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Protein expressions of Bmi-1 and Ki67 in sixty CRC, 30 adenomas and 20 normal colorectal mucosal tissues were detected using immunohistochemistry.
  • RESULTS: The expression rates of Bmi-1 and Ki67 were 25.0%, 6.7%, 0% and 18.3%, 3.3% and 0% in CRC, adenomas and normal colorectal mucosal tissues, respectively.
  • The expression of Bim-1 and Ki67 were significantly higher in CRC than in adenomas and normal colorectal mucosal tissues (P<0.05).
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenoma / metabolism. Adenoma / pathology. Adult. Age Factors. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Intestinal Mucosa / metabolism. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Polycomb Repressive Complex 1. Prognosis. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080002.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BMI1 protein, human; 0 / Ki-67 Antigen; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / Repressor Proteins; EC 6.3.2.19 / Polycomb Repressive Complex 1
  •  go-up   go-down


79. Cai H, Dong RZ, Wu JH, Zhu HY, Wang YN, Shi YQ, Mo SJ: [Clinical analysis of 168 cases of multiple primary colorectal carcinoma]. Zhonghua Wai Ke Za Zhi; 2008 Mar 1;46(5):370-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fourteen patients (8.3%) were found with other malignancies out of large intestine, 41 patients (24.4%) with colorectal adenomas, 72 (42.9%) with adenoma carcinogenesis.
  • Prompt treatment of adenoma can reduce the occurrence of MPCC, and active and standard surgical treatment should be done for MPCC.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18785535.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


80. Shureiqi I, Wu Y, Chen D, Yang XL, Guan B, Morris JS, Yang P, Newman RA, Broaddus R, Hamilton SR, Lynch P, Levin B, Fischer SM, Lippman SM: The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis. Cancer Res; 2005 Dec 15;65(24):11486-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined whether this shift occurs in vitro in the human colon cancer cell line Caco-2 in association with the loss of terminal differentiation and apoptosis, or in vivo during the formation of colorectal adenomas in patients with familial adenomatous polyposis (FAP).
  • In FAP patients, 15-LOX-1 expression and activity were significantly down-regulated in adenomas (compared with paired nonneoplastic epithelial mucosa), whereas 5-LOX and 15-LOX-2 protein expressions and enzymatic activities were not.
  • We conducted a validation study with immunohistochemical testing in a second group of FAP patients; 15-LOX-1 expression was down-regulated in colorectal adenomas (compared with nonneoplastic epithelial mucosa) in 87% (13 of 15) of this group.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 2000 Feb 11;467(2-3):341-7 [10675566.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Feb 24;268(3):778-83 [10679282.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] J Natl Cancer Inst. 2000 Jul 19;92(14):1136-42 [10904086.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6846-50 [11156377.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):497-503 [11212240.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4879-84 [11406566.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6307-12 [11522616.001]
  • [Cites] Anal Biochem. 2001 Oct 15;297(2):183-90 [11673886.001]
  • [Cites] Cell. 2002 Jan 25;108(2):153-64 [11832206.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1178-83 [11861401.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2721-7 [11980674.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):243-7 [12584173.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9968-73 [12909723.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6170-3 [14559799.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2004 Jan;70(1):7-15 [14643174.001]
  • [Cites] Prostaglandins Other Lipid Mediat. 2004 Jan;73(1-2):111-22 [15165036.001]
  • [Cites] J Biol Chem. 2004 Jul 2;279(27):28028-35 [15123685.001]
  • [Cites] J Biol Chem. 1990 Mar 25;265(9):5113-20 [2318885.001]
  • [Cites] Cancer Res. 1994 Jun 15;54(12):3288-93 [8205551.001]
  • [Cites] J Biol Chem. 1998 Aug 21;273(34):21569-77 [9705287.001]
  • [Cites] Carcinogenesis. 1999 Oct;20(10):1985-95 [10506115.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):231-7 [15738985.001]
  • (PMID = 16357157.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K07 CA086970; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / K07 CA86970; United States / NCI NIH HHS / CA / P30 CA16672
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Linoleic Acids; 0 / RNA, Messenger; 5204-88-6 / 13-hydroxy-9,11-octadecadienoic acid; EC 1.13.11.33 / ALOX15B protein, human; EC 1.13.11.33 / Arachidonate 15-Lipoxygenase; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase
  • [Other-IDs] NLM/ NIHMS5001; NLM/ PMC1564070
  •  go-up   go-down


81. Kobayashi T: Long-term results of stereotactic gamma knife radiosurgery for pituitary adenomas. Specific strategies for different types of adenoma. Prog Neurol Surg; 2009;22:77-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of stereotactic gamma knife radiosurgery for pituitary adenomas. Specific strategies for different types of adenoma.
  • Long-term results of gamma knife radiosurgery for pituitary adenomas are presented and treatment strategies for different adenoma types are discussed.
  • Two hundred and sixty-seven patients with pituitary adenoma have been treated by gamma knife radiosurgery during the past 12 years.
  • There were 131 cases of nonfunctioning and 136 cases of functioning adenomas, in which 71 GH-producing, 33 PRL-producing and 32 ACTH-producing adenomas were included.
  • Micro- and small adenomas could be cured by gamma knife radiosurgery alone.
  • Surgical or chemical debulking was necessary before radiosurgery for a large tumor with extrasellar extension.
  • Nonfunctioning adenomas showed higher control rates than functioning adenomas even with lower dose treatment.
  • Cushing disease showed the best response because of the smallest tumor size with the highest dose treatment.
  • The rate of hormone normalization was also high in Cushing disease but lower in prolactinoma and lowest in acromegaly.
  • High-dose treatment was necessary for functioning adenomas to control tumor growth and oversecretion of hormones.
  • In conclusion, gamma knife radiosurgery was effective and safe for the treatment of pituitary adenomas.
  • However, the treatment strategies should be specific to each adenoma type according to the radiosensitivity, chemosensitivity and biological nature of the tumor.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / surgery. Acromegaly / surgery. Adenoma / surgery. Radiosurgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Child. Female. Follow-Up Studies. Growth Hormone-Secreting Pituitary Adenoma / pathology. Growth Hormone-Secreting Pituitary Adenoma / surgery. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Patient Satisfaction. Pituitary ACTH Hypersecretion / pathology. Pituitary ACTH Hypersecretion / surgery. Prolactinoma / pathology. Prolactinoma / surgery. Treatment Outcome. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18948721.001).
  • [ISSN] 0079-6492
  • [Journal-full-title] Progress in neurological surgery
  • [ISO-abbreviation] Prog Neurol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


82. Takahashi H, Hosono K, Uchiyama T, Sugiyama M, Sakai E, Endo H, Maeda S, Schaefer KL, Nakagama H, Nakajima A: PPARgamma Ligand as a Promising Candidate for Colorectal Cancer Chemoprevention: A Pilot Study. PPAR Res; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previously, CRC and adenoma were used as a target for chemopreventive agents, but it needs a long time to evaluate, however, ACF can be a surrogate marker of CRC even for a brief period.
  • Twenty-nine patients were divided into two groups, 20 were in the endoscopically normal control group and 9 were in the pioglitazone (15 mg/day) group, and ACF and adenoma were examined before and after 1-month treatment.
  • The number of ACF was significantly decreased (5.8 +/- 1.1 to 3.3 +/- 2.3) after 1 month of pioglitazone treatment, however, there was no significant change in the number of crypts/ACF or in the number and size of adenomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20814432.001).
  • [ISSN] 1687-4765
  • [Journal-full-title] PPAR research
  • [ISO-abbreviation] PPAR Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2929500
  •  go-up   go-down


83. Chen H, Pruhs Z, Starling JR, Mack E: Intraoperative parathyroid hormone testing improves cure rates in patients undergoing minimally invasive parathyroidectomy. Surgery; 2005 Oct;138(4):583-7; discussion 587-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • From January 1990 to June 2004, there were 345 consecutive patients with 1 degrees HPT and positive localization studies for a single parathyroid adenoma who were candidates for minimally invasive parathyroidectomy.
  • In contrast, among 188 group 2 patients, 170 (90%) had resection of a single parathyroid adenoma, a greater than 50% decrease in iPTH levels, and were cured.
  • Of these 18 patients, 9 had double adenomas and 9 had 3- or 4-gland hyperplasia.
  • [MeSH-minor] Adenoma / complications. Humans. Hyperplasia. Middle Aged. Parathyroid Glands / pathology. Parathyroid Neoplasms / complications. Retrospective Studies. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16269285.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Parathyroid Hormone
  •  go-up   go-down


84. Jaquet P, Gunz G, Saveanu A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Enjalbert A, Culler MD: Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol; 2005 Jul;153(1):135-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy.
  • OBJECTIVE: This study compared the potency of a somatostatin receptor (sstr)2-sstr5 analog, BIM-23244, of an sstr2-dopamine D2 receptor (sstr2-DAD2) molecule, BIM-23A387 and of new somatostatin-dopamine chimeric molecules with differing, enhanced affinities for sstr2, sstr5 and DAD2, BIM-23A758, BIM-23A760 and BIM-23A761, to suppress GH and prolactin (PRL) from 18 human GH adenomas that are partially responsive to octreotide or lanreotide.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. DOPAMINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15994755.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / BIM 23A760; 0 / BIM-23244; 0 / BIM-23A761; 0 / RNA, Messenger; 0 / Receptors, Dopamine D2; 0 / Receptors, Somatostatin; 0 / Recombinant Fusion Proteins; 0 / somatostatin receptor 2; 0 / somatostatin receptor 5; 12629-01-5 / Human Growth Hormone; 51110-01-1 / Somatostatin; 9002-62-4 / Prolactin; RWM8CCW8GP / Octreotide; VTD58H1Z2X / Dopamine
  •  go-up   go-down


85. Ju J, Hao X, Lee MJ, Lambert JD, Lu G, Xiao H, Newmark HL, Yang CS: A gamma-tocopherol-rich mixture of tocopherols inhibits colon inflammation and carcinogenesis in azoxymethane and dextran sulfate sodium-treated mice. Cancer Prev Res (Phila); 2009 Feb;2(2):143-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated the effects of a gamma-tocopherol-rich mixture of tocopherols (gamma-TmT, containing 57% gamma-T, 24% delta-T, and 13% alpha-T) on colon carcinogenesis in azoxymethane (AOM)/dextran sulfate sodium (DSS)-treated mice.
  • In the AOM/DSS-treated mice, dietary gamma-TmT treatment resulted in a significantly lower colon inflammation index (52% of the control) on day 7 and number of colon adenomas (9% of the control) on week 7. gamma-TmT treatment also resulted in higher apoptotic index in adenomas, lower prostaglandin E2, leukotriene B4, and nitrotyrosine levels in the colon, and lower prostaglandin E2, leukotriene B4, and 8-isoprostane levels in the plasma on week 7.
  • In experiment 2 with AOM/DSS- treated mice sacrificed on week 21, dietary 0.17% or 0.3% gamma-TmT treatment, starting 1 week before the AOM injection, significantly inhibited adenocarcinoma and adenoma formation in the colon (to 17-33% of the control).

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROSTAGLANDIN F2ALPHA .
  • Hazardous Substances Data Bank. L-TYROSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11494-9 [11005841.001]
  • [Cites] Mol Aspects Med. 2007 Oct-Dec;28(5-6):668-91 [17316780.001]
  • [Cites] Dig Dis Sci. 2002 Jun;47(6):1266-78 [12064801.001]
  • [Cites] Carcinogenesis. 2002 Jun;23(6):993-1001 [12082021.001]
  • [Cites] Free Radic Biol Med. 2002 Dec 1;33(11):1534-42 [12446211.001]
  • [Cites] FASEB J. 2002 Dec;16(14):1952-4 [12368234.001]
  • [Cites] J Nutr. 2003 Feb;133(2):528-32 [12566495.001]
  • [Cites] Am J Epidemiol. 2003 Feb 15;157(4):335-44 [12578804.001]
  • [Cites] Am J Clin Nutr. 2003 Mar;77(3):700-6 [12600864.001]
  • [Cites] FASEB J. 2003 May;17(8):816-22 [12724340.001]
  • [Cites] Cancer Sci. 2003 Nov;94(11):965-73 [14611673.001]
  • [Cites] Nutr Cancer. 2003;46(2):172-8 [14690793.001]
  • [Cites] Free Radic Biol Med. 2004 Jan 1;36(1):1-15 [14732286.001]
  • [Cites] BMC Cancer. 2003 Oct 1;3:25 [14521714.001]
  • [Cites] Mutat Res. 2004 Jul 13;551(1-2):245-54 [15225597.001]
  • [Cites] Nutr Cancer. 2004;49(1):72-80 [15456638.001]
  • [Cites] Cancer Sci. 2004 Sep;95(9):721-7 [15471557.001]
  • [Cites] Lab Invest. 1974 Apr;30(4):505-13 [4363166.001]
  • [Cites] Cancer Res. 1980 Apr;40(4):1329-31 [7357560.001]
  • [Cites] J Natl Cancer Inst. 1983 Jun;70(6):1107-11 [6574281.001]
  • [Cites] Anal Biochem. 1985 Feb 15;145(1):21-6 [4003760.001]
  • [Cites] J Natl Cancer Inst. 1986 May;76(5):939-42 [3457978.001]
  • [Cites] J Natl Cancer Inst. 1986 Jun;76(6):1157-62 [3458951.001]
  • [Cites] Cancer Lett. 1987 Apr;35(1):71-7 [3567889.001]
  • [Cites] Am J Clin Nutr. 1989 Mar;49(3):517-26 [2923084.001]
  • [Cites] Am J Clin Nutr. 1991 Apr;53(4 Suppl):1068S-1070S [1845366.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1771-5 [8446589.001]
  • [Cites] Hum Pathol. 1994 Nov;25(11):1160-71 [7959660.001]
  • [Cites] J Appl Physiol (1985). 1994 Dec;77(6):2912-7 [7896640.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1198-203 [7700313.001]
  • [Cites] Free Radic Biol Med. 1995 Sep;19(3):259-69 [7557540.001]
  • [Cites] Nutr Cancer. 1996;26(1):99-109 [8844726.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3217-22 [9096373.001]
  • [Cites] Chem Res Toxicol. 1997 Apr;10(4):401-7 [9114976.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Jul;6(7):487-91 [9232334.001]
  • [Cites] Am J Epidemiol. 1997 Aug 1;146(3):231-43 [9247007.001]
  • [Cites] Nutr Cancer. 1998;31(3):168-77 [9795968.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1225-30 [10096552.001]
  • [Cites] Jpn J Cancer Res. 1999 Apr;90(4):399-405 [10363577.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17825-30 [15596715.001]
  • [Cites] Food Chem Toxicol. 1999 Sep-Oct;37(9-10):985-92 [10541455.001]
  • [Cites] Ann N Y Acad Sci. 2004 Dec;1031:399-400 [15753180.001]
  • [Cites] J Natl Cancer Inst. 2005 Apr 6;97(7):481-8 [15812073.001]
  • [Cites] BMC Cancer. 2005;5:46 [15892897.001]
  • [Cites] JAMA. 2005 Jul 6;294(1):56-65 [15998891.001]
  • [Cites] Carcinogenesis. 2006 Jan;27(1):162-9 [16081511.001]
  • [Cites] BMC Cancer. 2006;6:13 [16417629.001]
  • [Cites] Arch Biochem Biophys. 2006 Mar 15;447(2):97-106 [16530159.001]
  • [Cites] J Am Coll Nutr. 2006 Aug;25(4):292-9 [16943450.001]
  • [Cites] Nutr Cancer. 2006;56(1):82-5 [17176221.001]
  • [Cites] Nutr Cancer. 2007;59(1):62-9 [17927503.001]
  • [Cites] Nutr Cancer. 2007;59(1):76-81 [17927505.001]
  • [Cites] Environ Mol Mutagen. 2002;39(2-3):271-8 [11921198.001]
  • (PMID = 19155443.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA072720; United States / NIEHS NIH HHS / ES / ES05022; United States / NIEHS NIH HHS / ES / P30 ES005022; United States / NCI NIH HHS / CA / P30 CA072720-12; United States / NIEHS NIH HHS / ES / ES005022-109003; United States / NIEHS NIH HHS / ES / P30 ES005022-109003; United States / NCI NIH HHS / CA / CA72720; United States / NCI NIH HHS / CA / CA072720-12
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Carcinogens; 1HGW4DR56D / Leukotriene B4; 27415-26-5 / 8-epi-prostaglandin F2alpha; 3604-79-3 / 3-nitrotyrosine; 42HK56048U / Tyrosine; 8EF1Z1238F / gamma-Tocopherol; 9042-14-2 / Dextran Sulfate; B7IN85G1HY / Dinoprost; K7Q1JQR04M / Dinoprostone; MO0N1J0SEN / Azoxymethane
  • [Other-IDs] NLM/ NIHMS172441; NLM/ PMC2821738
  •  go-up   go-down


86. Chen ZQ, Fang XY: Adenoma of nonpigmented epithelium in ciliary body: literature review and case report. J Zhejiang Univ Sci B; 2007 Sep;8(9):612-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoma of nonpigmented epithelium in ciliary body: literature review and case report.
  • Adenomas of the nonpigmented ciliary epithelium (NPCE) are often clinically indistinguishable from amelanotic malignant melanomas of the ciliary body or metastatic carcinomas.
  • This paper reports a case study of a distinctive variant of adenoma of the NPCE, which clinically appears as epiretinal membrane in the macular region.
  • Histopathologic studies have revealed this is an adenoma of the NPCE.
  • Identification of this clinic feature is important because it will miss the diagnosis of the adenoma of the NPCE.
  • In this case study, B-scan ultrasonography as well as computerized tomography (CT) has been used to provide help in diagnosing the ciliary body tumor.
  • [MeSH-major] Adenoma / pathology. Ciliary Body / pathology. Epithelium, Corneal / pathology. Uveal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Ophthalmol Scand. 2000 Aug;78(4):470-3 [10990055.001]
  • [Cites] Mol Vis. 2004 Jan 15;10:31-6 [14737065.001]
  • [Cites] J Exp Med. 2004 Aug 2;200(3):367-76 [15289505.001]
  • [Cites] J Clin Pathol. 2004 Sep;57(9):997-8 [15333668.001]
  • [Cites] Ophthalmology. 1983 Dec;90(12):1528-30 [6677852.001]
  • [Cites] Can J Ophthalmol. 1991 Oct;26(6):328-33 [1751917.001]
  • [Cites] Retina. 1994;14(5):452-6 [7899722.001]
  • [Cites] Indian J Ophthalmol. 1995 Sep;43(3):137-40 [8822491.001]
  • [Cites] Ophthalmology. 1996 Dec;103(12):2007-16 [9003334.001]
  • [Cites] Arch Ophthalmol. 1999 Jan;117(1):113-6 [9930172.001]
  • [Cites] Am J Ophthalmol. 2005 Jan;139(1):188-90 [15652849.001]
  • [Cites] Ophthalmology. 2005 Jul;112(7):1218-21 [15921749.001]
  • [Cites] Prog Retin Eye Res. 2006 Mar;25(2):149-64 [16377232.001]
  • [Cites] Eur J Ophthalmol. 2006 Jul-Aug;16(4):630-3 [16952109.001]
  • [Cites] Biochem Pharmacol. 2006 Oct 30;72(9):1153-60 [16965764.001]
  • [Cites] Trans Am Ophthalmol Soc. 2005;103:537-67 [17057817.001]
  • [Cites] Eur J Cancer. 2006 Apr;42(6):745-50 [16517151.001]
  • (PMID = 17726740.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] China
  • [Number-of-references] 15
  • [Other-IDs] NLM/ PMC1963425
  •  go-up   go-down


87. Bouygues V, Meurette G, Bossard C, Cassagnau E, Le Rhun M, Lehur PA: [Recurrent adenomas in ileal pouch following ileoanal anastomosis for familial adenomatous polyposis]. Gastroenterol Clin Biol; 2008 May;32(5 Pt 1):525-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrent adenomas in ileal pouch following ileoanal anastomosis for familial adenomatous polyposis].
  • The authors report the case of recurrent endoileal pouch adenoma.
  • [MeSH-major] Adenoma. Adenomatous Polyposis Coli / surgery. Anal Canal / surgery. Colonic Pouches. Ileum / surgery. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18400433.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


88. Muhr C: Positron emission tomography in acromegaly and other pituitary adenoma patients. Neuroendocrinology; 2006;83(3-4):205-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron emission tomography in acromegaly and other pituitary adenoma patients.
  • OBSERVATIONS: 11C-raclopride, a specific dopamine antagonist, demonstrated high amounts of dopamine D2 binding in prolactinomas and some growth hormone-secreting adenomas.
  • The growth hormone adenomas also showed high metabolic rates.
  • PET was also shown valuable in differential diagnosing between pituitary adenomas, meningiomas and skull base neuromas.
  • CONCLUSION: We have found PET to be highly valuable in the research and clinical handling of patients with a pituitary adenoma for in vivo tumor characterization.
  • [MeSH-major] Acromegaly / radionuclide imaging. Adenoma / radionuclide imaging. Brain Mapping. Pituitary Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17047384.001).
  • [ISSN] 0028-3835
  • [Journal-full-title] Neuroendocrinology
  • [ISO-abbreviation] Neuroendocrinology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Dopamine Antagonists; 0 / Radiopharmaceuticals; 0 / Receptors, Dopamine D2; 430K3SOZ7G / Raclopride
  •  go-up   go-down


89. Kumar PV, Shirazi M, Salehi M: A diagnostic pitfall of fine needle aspiration cytology in testicular papillary serous cyst adenoma: a case report. Acta Cytol; 2009 Jul-Aug;53(4):467-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A diagnostic pitfall of fine needle aspiration cytology in testicular papillary serous cyst adenoma: a case report.
  • We describe the first fine needle aspiration biopsy (FNAB) finding of this type of tumor.
  • Based on clinical observation, we hypothesized that it was a malignant tumor.
  • A right radical orchiectomy was performed, and histologic tissue examination was used to diagnose the tumor as a benign papillary serous cystadenoma.
  • CONCLUSION: Papillary serous cystadenoma of the testis is a rare tumor.
  • The cytologic findings of this tumor are confusing and difficult to diagnose.
  • Clusters of epithelial cells with a high nuclear to cytoplasm ratio are mistaken for features of a malignant tumor.

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697740.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Caruso M, Moore J, Goodall GJ, Thomas M, Phillis S, Tyskin A, Cheetham G, Lerda N, Takahashi H, Ruszkiewicz A: Over-expression of cathepsin E and trefoil factor 1 in sessile serrated adenomas of the colorectum identified by gene expression analysis. Virchows Arch; 2009 Mar;454(3):291-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Over-expression of cathepsin E and trefoil factor 1 in sessile serrated adenomas of the colorectum identified by gene expression analysis.
  • Sessile serrated adenomas are now recognised as precursor lesions of a substantial subset of colorectal cancers arising via a so-called "serrated pathway".
  • The aim of our study was to identify differentially expressed genes in sessile serrated adenomas and conventional adenomas.
  • Further studies using quantitative real-time polymerase chain reaction on cathepsin E (CTSE) demonstrated a significantly (p < 0.05) higher expression in sessile serrated adenomas as compared to hyperplastic polyp and tubular adenomas.
  • Trefoil Factor 1 showed the same trend of expression for sessile serrated adenomas as compared to hyperplastic polyps and was significantly higher in both polyps compared to tubular adenomas.
  • Immunohistochemistry for both proteins demonstrated strong cytoplasmic staining of abnormal crypts in all sessile serrated adenomas, while staining in tubular adenomas and hyperplastic polyps was absent or weak and focal.
  • The findings demonstrated the positive association of the BRAF mutation, V600E, with sessile serrated adenomas and KRAS mutations with tubular adenomas (p < 0.05).
  • This study demonstrates the over-expression in CTSE, in particular, and TFF1 in sessile serrated adenomas compared to both hyperplastic polyps and tubular adenomas.
  • [MeSH-major] Adenoma / genetics. Biomarkers, Tumor / analysis. Cathepsin E / biosynthesis. Colorectal Neoplasms / genetics. Tumor Suppressor Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. ArrayExpress: Data: Microarray .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2006 Aug;49(2):121-31 [16879389.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1452-9 [15489648.001]
  • [Cites] Am J Surg Pathol. 1990 Jun;14(6):524-37 [2186644.001]
  • [Cites] Trends Endocrinol Metab. 2008 Mar;19(2):74-81 [18054496.001]
  • [Cites] J Pathol. 2001 Mar;193(3):283-5 [11241405.001]
  • [Cites] Hum Pathol. 1990 Mar;21(3):260-70 [2312104.001]
  • [Cites] Nucleic Acids Res. 1984 Mar 26;12(6):2861-78 [6324130.001]
  • [Cites] Gastroenterology. 1991 Feb;100(2):375-9 [1985035.001]
  • [Cites] Virchows Arch. 2007 Jun;450(6):613-8 [17450379.001]
  • [Cites] Am J Pathol. 1997 Apr;150(4):1223-9 [9094979.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):65-81 [12502929.001]
  • [Cites] Am J Pathol. 2002 Feb;160(2):529-36 [11839573.001]
  • [Cites] Histochem Cell Biol. 2007 Nov;128(5):445-55 [17851679.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Br J Cancer. 2007 Apr 23;96(8):1166-9 [17375050.001]
  • [Cites] Digestion. 2006;74(1):33-9 [17068395.001]
  • [Cites] Virchows Arch. 1994;424(6):601-6 [8055153.001]
  • [Cites] J Histochem Cytochem. 2006 Dec;54(12 ):1335-48 [16924127.001]
  • [Cites] Histochemistry. 1993 Mar;99(3):201-11 [8491674.001]
  • [Cites] Int J Cancer. 1994 Jan 2;56(1):52-5 [7505265.001]
  • [Cites] Int J Cancer. 1996 Aug 7;67(4):492-7 [8759606.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1619-26 [15753353.001]
  • [Cites] J Pathol. 1999 Apr;187(5):499-502 [10398112.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4878-81 [12941809.001]
  • [Cites] World J Gastroenterol. 2006 Dec 7;12 (45):7361-4 [17143957.001]
  • [Cites] Anticancer Res. 1996 Jul-Aug;16(4B):2351-5 [8694568.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):705-8 [12598303.001]
  • [Cites] Endocrinology. 1987 Nov;121(5):1759-65 [3665845.001]
  • [Cites] Tumour Biol. 2006;27(1):36-42 [16340248.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] Gut. 2000 Jul;47(1):37-42 [10861262.001]
  • [Cites] Gastroenterology. 1990 Jun;98(6):1655-65 [1692551.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Mar 14;367(3):517-22 [18178150.001]
  • [Cites] J R Coll Physicians Lond. 1997 Jan-Feb;31(1):37-41 [9044196.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):380-91 [16191506.001]
  • [Cites] J Biol Chem. 1989 Oct 5;264(28):16748-53 [2674141.001]
  • [Cites] Stat Appl Genet Mol Biol. 2004;3:Article3 [16646809.001]
  • [Cites] Nucleic Acids Res. 2002 Feb 15;30(4):e15 [11842121.001]
  • [Cites] Oncogene. 2006 Oct 26;25(50):6628-36 [16715141.001]
  • [Cites] Gut. 2004 Aug;53(8):1137-44 [15247181.001]
  • [Cites] Nature. 2002 Aug 29;418(6901):934 [12198537.001]
  • [Cites] Mod Pathol. 1993 Jul;6(4):446-8 [8415590.001]
  • [Cites] Brief Bioinform. 2001 Dec;2(4):341-9 [11808746.001]
  • [Cites] Anal Quant Cytol Histol. 2007 Oct;29(5):326-32 [17987813.001]
  • [Cites] J Immunol. 2005 Feb 15;174(4):1791-800 [15699105.001]
  • [Cites] Mod Pathol. 2008 Jun;21(6):660-9 [18360351.001]
  • [Cites] J Histochem Cytochem. 2007 May;55(5):505-13 [17242463.001]
  • [Cites] J Gastroenterol Hepatol. 2000 Nov;15(11):1333-8 [11129230.001]
  • [Cites] Am J Surg Pathol. 2008 Jan;32(1):21-9 [18162766.001]
  • [Cites] Am J Surg Pathol. 2008 Jan;32(1):30-5 [18162767.001]
  • [Cites] Gut. 2000 Jul;47(1):43-9 [10861263.001]
  • [Cites] Pathol Res Pract. 1994 Apr;190(4):342-9 [8078803.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):265-70 [11120884.001]
  • [Cites] Eur J Histochem. 2003;47(2):143-50 [12777211.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2006 Mar;14 (1):31-6 [16540727.001]
  • [Cites] Am J Clin Pathol. 2003 Jun;119(6):778-96 [12817424.001]
  • [Cites] J Natl Cancer Inst. 2001 Sep 5;93(17 ):1307-13 [11535705.001]
  • [Cites] J Pathol. 2005 Nov;207 (3):285-94 [16177963.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):815-22 [12598316.001]
  • [Cites] Histopathology. 2007 Jan;50(1):131-50 [17204027.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12 ):1491-501 [17122504.001]
  • [Cites] Oncogene. 2007 Jan 11;26(2):312-20 [16819509.001]
  • [Cites] Am J Pathol. 1993 Mar;142(3):663-8 [7681255.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6451-5 [12438234.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jan;2(1):1-8 [15017625.001]
  • (PMID = 19172291.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / TFF1 protein, human; 0 / Trefoil Factor-1; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.4.23.34 / Cathepsin E; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras); EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


91. Jurek D, Fleckl E, Marian B: Bile acid induced gene expression in LT97 colonic adenoma cells. Food Chem Toxicol; 2005 Jan;43(1):87-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bile acid induced gene expression in LT97 colonic adenoma cells.
  • LT97 human colonic adenoma cells reflecting early premalignant genotype and growth characteristics have been posed to tumor promoting bile acids in order to identify marker genes that permit identification of tumor promoters in vitro.
  • Physiologically relevant concentrations of desoxycholate (DOC) and chenodesoxycholate (CDC) upregulated expression of c-fos and COX-2 in a concentration- and time-dependent manner.
  • Transient induction of c-fos was seen with the non-promoting taurodesoxycholate (TDOC) as well as DOC, however extended induction at 3 h was only achieved by DOC and CDC reaching 3-6-fold as compared to the control.
  • Stimulation of COX-2 expression was completely specific for the tumor promoting analogs DOC and CDC.
  • Expression of VEGF was stimulated 4-5-fold in the tumor promoter (DOC and CDC) groups and about 2-fold in the non-promoting controls TDOC and GCDC.
  • At later times the tumor promoter specific difference was lost.
  • Our results show that all three genes are modulated in a tumor promoter dependent way and that their upregulation in LT97 adenoma cells can be used for in vitro testing of colon tumor promoters and chemopreventive compounds.
  • [MeSH-major] Adenoma / metabolism. Bile Acids and Salts / pharmacology. Biomarkers, Tumor / metabolism. Colonic Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / drug effects
  • [MeSH-minor] Cell Line, Tumor. Chenodeoxycholic Acid / pharmacology. Cyclooxygenase 2. Deoxycholic Acid / pharmacology. Dose-Response Relationship, Drug. Gene Amplification. Glyceraldehyde-3-Phosphate Dehydrogenases / metabolism. Humans. Isoenzymes / genetics. Isoenzymes / metabolism. Membrane Proteins. Polymerase Chain Reaction. Prostaglandin-Endoperoxide Synthases / genetics. Prostaglandin-Endoperoxide Synthases / metabolism. Proto-Oncogene Proteins c-fos / genetics. Proto-Oncogene Proteins c-fos / metabolism. RNA / isolation & purification. Taurodeoxycholic Acid / pharmacology. Time Factors. Tumor Necrosis Factor-alpha / metabolism. Up-Regulation / drug effects. Up-Regulation / physiology. Vascular Endothelial Growth Factor A / genetics. Vascular Endothelial Growth Factor A / metabolism

  • Hazardous Substances Data Bank. DEOXYCHOLIC ACID .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15582199.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bile Acids and Salts; 0 / Biomarkers, Tumor; 0 / Isoenzymes; 0 / Membrane Proteins; 0 / Proto-Oncogene Proteins c-fos; 0 / Tumor Necrosis Factor-alpha; 0 / Vascular Endothelial Growth Factor A; 005990WHZZ / Deoxycholic Acid; 0GEI24LG0J / Chenodeoxycholic Acid; 516-50-7 / Taurodeoxycholic Acid; 63231-63-0 / RNA; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases
  •  go-up   go-down


92. Sjödin A, Guo D, Lund-Johansen M, Krossnes BK, Lilleng P, Henriksson R, Hedman H: Secretoglobins in the human pituitary: high expression of lipophilin B and its down-regulation in pituitary adenomas. Acta Neuropathol; 2005 Apr;109(4):381-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secretoglobins in the human pituitary: high expression of lipophilin B and its down-regulation in pituitary adenomas.
  • Antibodies specific for the secretoglobin lipophilin B (SCGB1D2, BU101) were developed and used in an immunohistochemical analysis of a human normal tissue microarray.
  • Eight of nine analyzed pituitary adenomas showed a reduction in lipophilin B immunoreactivity compared to normal pituitary.
  • However, there was no apparent association between lipophilin B immunoreactivity and hormone production or tumor invasiveness.
  • Expression of eight different secretoglobin mRNAs were analyzed in normal pituitary and the pituitary adenoma cell line HP75 by highly specific quantitative real-time reverse transcription-PCR assays.
  • The present report demonstrates, for the first time, lipophilin B expression in the pituitary and its apparent down-regulation in pituitary adenomas.
  • [MeSH-major] Adenoma / metabolism. Gene Expression Regulation, Neoplastic / physiology. Myelin Proteins / metabolism. Pituitary Gland / metabolism. Pituitary Neoplasms / metabolism. Proteolipids / metabolism
  • [MeSH-minor] Blotting, Western / methods. Cell Line, Tumor. Humans. Immunohistochemistry / methods. Mammaglobin B. RNA, Messenger / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction / methods. Secretoglobins. Uteroglobin

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15668787.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Mammaglobin B; 0 / Myelin Proteins; 0 / Proteolipids; 0 / RNA, Messenger; 0 / SCGB1D2 protein, human; 0 / SCGB2A1 protein, human; 0 / Secretoglobins; 9060-09-7 / Uteroglobin
  •  go-up   go-down


93. van den Bergh AC, van den Berg G, Schoorl MA, Sluiter WJ, van der Vliet AM, Hoving EW, Szabó BG, Langendijk JA, Wolffenbuttel BH, Dullaart RP: Immediate postoperative radiotherapy in residual nonfunctioning pituitary adenoma: beneficial effect on local control without additional negative impact on pituitary function and life expectancy. Int J Radiat Oncol Biol Phys; 2007 Mar 1;67(3):863-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immediate postoperative radiotherapy in residual nonfunctioning pituitary adenoma: beneficial effect on local control without additional negative impact on pituitary function and life expectancy.
  • PURPOSE: To demonstrate the benefit of immediate postoperative radiotherapy in residual nonfunctioning pituitary adenoma (NFA) in perspective to the need for hormonal substitution and life expectancy.
  • [MeSH-major] Adenoma / radiotherapy. Life Expectancy. Pituitary Gland / radiation effects. Pituitary Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Hormone Replacement Therapy. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197121.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Colvin M, Delis A, Bracamonte E, Villar H, Leon LR Jr: Infiltrating adenocarcinoma arising in a villous adenoma of the anal canal. World J Gastroenterol; 2009 Jul 28;15(28):3560-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infiltrating adenocarcinoma arising in a villous adenoma of the anal canal.
  • In particular, adenomas and adenocarcinomas are distinctly rare entities in this region.
  • We describe an infiltrating, well-differentiated adenocarcinoma arising in a villous adenoma from the distal anal canal, in an otherwise healthy patient at low risk for gastrointestinal malignancy.
  • Microscopic evaluation revealed an infiltrating well-differentiated adenocarcinoma, arising from a villous adenoma.
  • Our report is the first describing the possible malignant degeneration of a villous adenoma in the anal canal.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Villous / pathology. Anal Canal / pathology
  • [MeSH-minor] Aged, 80 and over. Cell Transformation, Neoplastic / pathology. Disease Progression. Humans. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Surg. 2000 Aug;66(8):789-92 [10966042.001]
  • [Cites] Colorectal Dis. 2008 Jul;10(6):621-3 [17949443.001]
  • [Cites] Histopathology. 2002 Mar;40(3):302-4 [11895502.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10):1320-4 [14530668.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):249-62 [15137955.001]
  • [Cites] Cancer. 1975 Dec;36(6):2251-70 [1203876.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] Br J Surg. 1994 Apr;81(4):500-8 [8205420.001]
  • [Cites] Br J Surg. 1995 Dec;82(12):1634 [8548224.001]
  • [Cites] J Clin Pathol. 2005 Feb;58(2):217-9 [15677547.001]
  • [Cites] World J Gastroenterol. 2006 Mar 21;12(11):1780-1 [16586552.001]
  • [Cites] Colorectal Dis. 2006 May;8(4):296-301 [16630233.001]
  • [Cites] Eur J Dermatol. 2006 Sep-Oct;16(5):576-8 [17101482.001]
  • [Cites] World J Gastroenterol. 2006 Dec 7;12(45):7304-8 [17143945.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Nov;33(12):1977-9 [17212165.001]
  • [Cites] Oncologist. 2007 May;12(5):524-34 [17522240.001]
  • [Cites] Surg Today. 2007;37(7):596-9 [17593481.001]
  • [Cites] Tech Coloproctol. 2007 Dec;11(4):340-2 [18060528.001]
  • [Cites] J Am Osteopath Assoc. 2001 Aug;101(8):450-3 [11526879.001]
  • (PMID = 19630115.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2715986
  •  go-up   go-down


95. Harvey NT, Ruszkiewicz A: Serrated neoplasia of the colorectum. World J Gastroenterol; 2007 Jul 28;13(28):3792-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serrated neoplasia of the colorectum.
  • Serrated polyps of the colorectum form a group of related lesions which include aberrant crypt foci (ACF), conventional hyperplastic polyps, mixed (admixed) polyps, serrated adenomas and sessile serrated adenomas.
  • In particular, the sessile serrated adenoma has become recognised as the precursor lesion to a group of sporadic colorectal carcinomas characterised by morphological and molecular features distinct from conventional adenomas.
  • These recent findings have challenged the long held paradigm that all colorectal carcinomas arise via the traditional adenoma-carcinoma sequence.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Colonic Polyps / pathology. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17657832.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] China
  • [Number-of-references] 57
  • [Other-IDs] NLM/ PMC4611210
  •  go-up   go-down


96. Emmolo I, Corso HD, Borretta G, Visconti G, Piovesan A, Cesario F, Borghi F: Unexpected results using rapid intraoperative parathyroid hormone monitoring during parathyroidectomy for primary hyperparathyroidism. World J Surg; 2005 Jun;29(6):785-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rapid intraoperative parathyroid hormone (RIOPTH) monitoring predicts complete removal of all hypersecreting tissue by means of a significant parathyroid hormone (PTH) decrease.
  • (1) spikes: a PTH increase 10 minutes after removal of the diseased gland was observed in three patients;.
  • (3) false-positive results: five patients with multiglandular disease showed a PTH decrease to a cure level despite excision of one adenoma only (in two of these patients a 20-minute sample showed a PTH increase soon after manipulation of the second adenoma).
  • We concluded that the spike, almost certainly a consequence of manipulating the adenoma, when detected should be considered the "true" baseline value.
  • False-positive results are usually related to a double adenoma, one functionally prevailing over the other.
  • Because in our experience manipulation of the second adenoma brought a PTH increase detected with RIOPTH monitoring, we believe that the second adenoma should be excised.

  • Genetic Alliance. consumer health - Hyperparathyroidism, primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2003 May;237(5):714-9; discussion 719-21 [12724638.001]
  • [Cites] J Chir (Paris). 1988 Nov;125(11):631-7 [3066794.001]
  • [Cites] Surgery. 1991 Dec;110(6):1035-42 [1745972.001]
  • [Cites] Surgery. 1999 Dec;126(6):1145-50; discussion 1150-1 [10598200.001]
  • [Cites] World J Surg. 2002 Aug;26(8):926-30 [11965444.001]
  • [Cites] Surgery. 1996 Dec;120(6):934-6; discussion 936-7 [8957476.001]
  • [Cites] World J Surg. 1990 May-Jun;14(3):349-53; discussion 353-4 [2368437.001]
  • [Cites] Surgery. 2001 Dec;130(6):1005-10 [11742330.001]
  • [Cites] Surgery. 1978 Sep;84(3):384-93 [98860.001]
  • [Cites] World J Surg. 2002 Aug;26(8):1074-7 [12016487.001]
  • [Cites] Ann Surg. 2002 Jul;236(1):105-11 [12131092.001]
  • [Cites] Surgery. 1996 Dec;120(6):954-8 [8957480.001]
  • [Cites] Surgery. 2000 Dec;128(6):925-9;discussion 935-6 [11114625.001]
  • [Cites] World J Surg. 2002 Aug;26(8):921-5 [12016471.001]
  • [Cites] Surgery. 1999 Dec;126(6):1139-43; discussion 1143-4 [10598199.001]
  • [Cites] Surgery. 2003 Dec;134(6):973-9; discussion 979-81 [14668730.001]
  • [Cites] J Bone Miner Res. 2001 Apr;16(4):605-14 [11315988.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):821-7 [11448357.001]
  • [Cites] Am J Surg. 1991 Oct;162(4):299-302 [1683177.001]
  • [Cites] Clin Chem. 1998 Apr;44(4):805-9 [9554492.001]
  • [Cites] Surgery. 1999 Dec;126(6):1132-7; discussion 1137-8 [10598198.001]
  • [Cites] Surgery. 1999 Dec;126(6):1030-5 [10598184.001]
  • [Cites] Clin Nucl Med. 2000 Mar;25(3):173-8 [10698410.001]
  • [Cites] Surgery. 1988 Dec;104(6):1121-7 [3194839.001]
  • [Cites] Eur J Endocrinol. 2002 Jun;146(6):783-8 [12039698.001]
  • [Cites] Clin Chem. 2000 Oct;46(10):1662-8 [11017947.001]
  • [Cites] Arch Surg. 2002 Jun;137(6):659-68; discussion 668-9 [12049536.001]
  • [Cites] Arch Surg. 2001 Aug;136(8):945-9 [11485536.001]
  • [Cites] Ann Surg. 1994 May;219(5):574-9; discussion 579-81 [8185406.001]
  • [Cites] Horm Res. 2002;57(1-2):57-60 [12006722.001]
  • (PMID = 15883666.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Parathyroid Hormone
  •  go-up   go-down


97. Pawlikowski M: Immunohistochemical detection of angiotensin receptors AT1 and AT2 in normal rat pituitary gland, estrogen-induced rat pituitary tumor and human pituitary adenomas. Folia Histochem Cytobiol; 2006;44(3):173-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of angiotensin receptors AT1 and AT2 in normal rat pituitary gland, estrogen-induced rat pituitary tumor and human pituitary adenomas.
  • Male rat pituitary glands, diethylstilbestrol (DES)-induced rat pituitary tumors and 12 human pituitary adenomas were immunostained with antibodies raised against AT1 and AT2 angiotensin receptor proteins.
  • In human pituitary adenomas, weak AT1 immunostaining was found in 5 tumors.
  • In the remaining adenomas, the AT1 immunostaining was trace (doubtful) or absent.
  • In human pituitary adenomas, the tumoral cells were AT2- negative but moderate to strong AT2 immunostaining was observed in intratumoral blood vessel walls.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16977796.001).
  • [ISSN] 0239-8508
  • [Journal-full-title] Folia histochemica et cytobiologica
  • [ISO-abbreviation] Folia Histochem. Cytobiol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Estrogens; 0 / Receptor, Angiotensin, Type 1; 0 / Receptor, Angiotensin, Type 2; 0 / Receptors, Angiotensin; 731DCA35BT / Diethylstilbestrol
  •  go-up   go-down


98. Liu FZ, Dong MM, Zhu Y, Zhang Y, Fan QH: [Clinical features of parathyroid space-occupying lesions]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 Apr;44(4):282-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 2 cases of parathyroid cancer, 29 cases of parathyroid adenoma, 11 cases of parathyroid cysts in this study.
  • Twenty nine cases of parathyroid adenoma were treated with operation, 28 patients achieved complete remission, 1 suffered relapse after 23 months postoperative follow up.
  • Tumor resection can be performed for parathyroid cysts, intraoperative exploration of bilateral neck is indicated for parathyroid adenoma, and a radical resection should be performed primarily for the parathyroid cancer.

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19558832.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Parathyroid Hormone; SY7Q814VUP / Calcium
  •  go-up   go-down


99. Hays T, Rusyn I, Burns AM, Kennett MJ, Ward JM, Gonzalez FJ, Peters JM: Role of peroxisome proliferator-activated receptor-alpha (PPARalpha) in bezafibrate-induced hepatocarcinogenesis and cholestasis. Carcinogenesis; 2005 Jan;26(1):219-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In mice fed bezafibrate for 1 year, preneoplastic foci, adenomas and a hepatocellular carcinoma were found in (+/+) mice, while only a single microscopic adenoma was found in one (-/-) mouse.
  • [MeSH-minor] Acyl-CoA Oxidase / drug effects. Acyl-CoA Oxidase / metabolism. Animals. Bile Acids and Salts / metabolism. Blotting, Northern. Cell Cycle Proteins / drug effects. Cell Cycle Proteins / metabolism. Cytochrome P-450 CYP4A / drug effects. Cytochrome P-450 CYP4A / metabolism. DNA Repair Enzymes / drug effects. DNA Repair Enzymes / metabolism. DNA-Binding Proteins / drug effects. DNA-Binding Proteins / metabolism. Disease Models, Animal. Male. Mice. RNA, Messenger / analysis. Receptors, Cytoplasmic and Nuclear. Transcription Factors / drug effects. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15447978.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA89607; United States / NCI NIH HHS / CA / CA97999
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bile Acids and Salts; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / PPAR alpha; 0 / Peroxisome Proliferators; 0 / RNA, Messenger; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Transcription Factors; 0 / farnesoid X-activated receptor; EC 1.14.15.3 / Cytochrome P-450 CYP4A; EC 1.3.3.6 / Acyl-CoA Oxidase; EC 6.5.1.- / DNA Repair Enzymes; Y9449Q51XH / Bezafibrate
  •  go-up   go-down


100. Weston BR, Iyer RB, Qiao W, Lee JH, Bresalier RS, Ross WA: Ability of integrated positron emission and computed tomography to detect significant colonic pathology: the experience of a tertiary cancer center. Cancer; 2010 Mar 15;116(6):1454-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ability of integrated positron emission and computed tomography to detect significant colonic pathology: the experience of a tertiary cancer center.
  • Lesions not detected by PET-CT included 4 colon cancers, 7 advanced adenomas, and 10 patients with colonic lymphoma.
  • For detecting colon cancer and adenomas 10 mm or more, the sensitivity, specificity, PPV, NPV, and accuracy of PET-CT were 72%, 90%, 45%, 96%, and 88%, respectively.
  • However, negative PET-CT does not rule out significant colonic pathology including colon cancer, advanced adenomas, or lymphoma.
  • [MeSH-minor] Adenoma / diagnosis. Colonoscopy. Deoxyglucose. False Positive Reactions. Female. Humans. Incidental Findings. Lymphoma / diagnosis. Male. Middle Aged. Radiopharmaceuticals. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 2-DEOXY-D-GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20143447.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 9G2MP84A8W / Deoxyglucose
  •  go-up   go-down






Advertisement